

DISSERTATIONS IN
**HEALTH
SCIENCES**

MARJA RUOTSALAINEN

*Do Wheezing Infants Grow
Up to be Asthmatic Adults?*

*Asthma Prevalence in Relation to Early-Life and
Current Risk Factors*

PUBLICATIONS OF THE UNIVERSITY OF EASTERN FINLAND
Dissertations in Health Sciences



UNIVERSITY OF
EASTERN FINLAND

MARJA RUOTSALAINEN

*Do wheezing infants grow up to be
asthmatic adults?*

Asthma prevalence in relation to early-life and current risk factors

To be presented by permission of the Faculty of Health Sciences, University of Eastern Finland for public examination in Auditorium L3, Canthia, University of Eastern Finland, Kuopio, on Friday, January 24th 2014, at 12 noon

Publications of the University of Eastern Finland
Dissertations in Health Sciences
Number 211

Department of Pediatrics, Kuopio University Hospital and
Institute of Clinical Medicine, School of Medicine, Faculty of Health Sciences,
University of Eastern Finland
Kuopio
2013

Kopijyvä
Kuopio, 2013

Series Editors:

Professor Veli-Matti Kosma, M.D., Ph.D.
Institute of Clinical Medicine, Pathology
Faculty of Health Sciences

Professor Hannele Turunen, Ph.D.
Department of Nursing Science
Faculty of Health Sciences

Professor Olli Gröhn, Ph.D.
A.I. Virtanen Institute for Molecular Sciences
Faculty of Health Sciences

Professor Kai Kaarniranta, M.D., Ph.D.
Institute of Clinical Medicine, Ophthalmology
Faculty of Health Sciences

Lecturer Veli-Pekka Ranta, Ph.D. (pharmacy)
School of Pharmacy
Faculty of Health Sciences

Distributor:

University of Eastern Finland
Kuopio Campus Library
P.O.Box 1627
FI-70211 Kuopio, Finland
<http://www.uef.fi/kirjasto>

ISBN (print): 978-952-61-1344-9

ISBN (pdf): 978-952-61-1345-6

ISSN (print): 1798-5706

ISSN (pdf): 1798-5714

ISSN-L: 1798-5706

- Author's address: Department of Pediatrics
Kuopio University Hospital and
University of Eastern Finland
KUOPIO
FINLAND
- Supervisors: Professor Matti Korppi, M.D., Ph.D.
Center for Child Health Research
Tampere University and University Hospital
TAMPERE
FINLAND
- Eija Piippo-Savolainen, M.D., Ph.D.
Department of Pediatrics
Kuopio University Hospital and
University of Eastern Finland
KUOPIO
FINLAND
- Reviewers: Professor Hannu Kankaanranta, M.D., Ph.D.
Department of Respiratory Diseases
Seinäjoki Central Hospital and University of Tampere
SEINÄJOKI
FINLAND
- Docent Tuomas Jartti, M.D., Ph.D.
Department of Pediatrics
University of Turku
TURKU
FINLAND
- Opponent: Professor Minna Kaila, M.D., Ph.D.
Hjelt Institute
The Faculty of Medicine
University of Helsinki
HELSINKI
FINLAND

Ruotsalainen, Marja

Do wheezing infants grow up to be asthmatic adults? Asthma prevalence in relation to early-life and current risk factors.

University of Eastern Finland, Faculty of Health Sciences

Publications of the University of Eastern Finland. Dissertations in Health Sciences Number. 2013 p.57

ISBN (print): 978-952-61-1344-9

ISBN (pdf): 978-952-61-1345-6

ISSN (print): 1798-5706

ISSN (pdf): 1798-5714

ISSN-L: 1798-5706

ABSTRACT

Wheezing associated with respiratory infection is common in infancy and early childhood. Viral bronchiolitis, especially if requiring hospitalization, is a major risk factor for subsequent wheezing and asthma. The link from bronchiolitis and subsequent asthma is dependent on host factors and virus-specific effects.

In 1981-1982, 130 infants aged 1-23 months were hospitalized for bronchiolitis or pneumonia. Clinical and laboratory data were collected on admission and during convalescence and at the follow-up visits until 20-35 months of age. The allergy and asthma status of the children was evaluated at 4.5-6 years, 8.5-10 years and 18-20 years of age. A selected control group with a family history of atopy was followed from birth. In 1992-1993, 100 infants aged 1-23 months were hospitalized for wheezing associated with respiratory infection. Clinical and laboratory data, including RSV and rhinovirus aetiology, were collected on entry. The asthma and allergy of the children were evaluated at the median ages of 4.0, 7.2 and 12.3 years.

In 2008, a postal questionnaire was sent to two cohorts (median ages 27.3 and 16.5 years), to a selected control group and to non-selected population based controls (Population Register Centre, Finland). The questions focused on asthma, allergy, smoking and weight status. Asthma was classified to doctor-diagnosed asthma and self-reported asthma.

In adulthood (cohort 1981-1982), doctor-diagnosed asthma was present in 20% of the former bronchiolitis patients, compared with 5% in two control groups. The respective figures for self-reported asthma were 41% and 7-10%. Current allergic rhinitis and smoking were associated with asthma, but overweight was not. Early-life wheezing was an independent risk factor of asthma, as was RSV hospitalization. In adolescence (1992-1993 cohort), doctor-diagnosed asthma was present in 30% of the former bronchiolitis patients but only in 5% of controls. The respective figures for self-reported asthma were 64% and 11%. Self-reported asthma was more common in the former rhinovirus (83%) than in the former RSV patients (48%). Overweight had no significant association with doctor-diagnosed or self-reported asthma, allergy or the use of inhaled corticosteroids. Atopic dermatitis in infancy was the only independently significant early life predictor of doctor-diagnosed asthma.

In conclusion, the increased asthma risk in children with early-life wheezing symptoms continues until at least 27 years of age. Hospitalization due to RSV in infancy is a risk factor for asthma in adolescence and adulthood, and in adolescence rhinovirus bronchiolitis had a greater impact on the risk of self-reported asthma. Weight status had no significant association with asthma or allergy in adolescence and in adulthood after hospitalization for bronchiolitis in infancy.

National Library of Medicine Classification: WC 207, WF 102, WF 150, WF 553, WS 280

Medical Subject Headings: Asthma/epidemiology; Asthma/diagnosis; Bronchiolitis; Child, Hospitalized; Follow-Up Studies; Hypersensitivity, Immediate; Pneumonia; Questionnaires; Respiratory Sounds; Respiratory Syncytial Virus Infections; Risk Factors

Ruotsalainen, Marja

Kasvaako vinkuvista vauvoista astmaisia aikuisia? Astman esiintyvyys suhteessa varhaisiin ja nykyisiin riskitekijöihin.

Itä-Suomen yliopisto, terveystieteiden tiedekunta

Publications of the University of Eastern Finland. Dissertations in Health Sciences Numero. 2013. 57 s.

ISBN (print): 978-952-61-1344-9

ISBN (pdf): 978-952-61-1345-6

ISSN (print): 1798-5706

ISSN (pdf): 1798-5714

ISSN-L: 1798-5706

TIIVISTELMÄ

Imeväisiässä ja varhaislapsuudessa vinkuna on yleistä hengitystieinfektion yhteydessä. Viruksen aiheuttama ilmatiehyttulehdus eli bronkioliitti, erityisesti johtaessaan sairaalahoitoon, lisää riskiä myöhempään vinkuna oireeseen ja astmaan. Bronkioliitin ja astman yhteys on riippuvainen potilaan taustoista ja virus spesifisistä tekijöistä.

Vuosina 1981–1982 kutsuttiin tutkimukseen 130 alle 2-vuotiasta lasta, joita hoidettiin sairaalassa bronkioliitin tai keuhkokuumeen vuoksi Sairaalahoitajakson aikana ja 4-6 viikkoa myöhemmin kerättiin lapsista tarkat taustatiedot ja otettiin laboratorionäytteitä. Tiedot hengitystieoireilusta kerättiin 20–35 kuukauden ikään asti ja kliiniset seuranta käynnit järjestettiin 4.5-6, 8.5–10 ja 18–20 vuoden ikäisinä, jolloin kartoitettiin tiedot allergioista ja astmasta. Kontrolliryhmänä toimivat terveet, atopia perhetaustan omaavat lapset. Vuosina 1992–1993 tutkimukseen kutsuttiin 100 samanikäistä lasta, joita hoidettiin sairaalassa alahengitystieinfektion aiheuttaman uloshengitysvaikeuden vuoksi. Heiltä kerättiin myös taustatiedot ja otettiin laboratorionäytteitä, mm. respiratory syncytial virus (RSV) ja rhinovirus näytteet, ja kliiniset kontrollikäynnit olivat 4.0, 7.2 ja 12.3 vuoden ikäisinä, jolloin kartoitettiin tiedot allergioista ja astmasta.

Vuonna 2008 tutkimukseen kerättiin kontrolliryhmä väestörekisterikeskuksesta vastaavan ikäisistä ihmisistä, joilla ei ollut taustalla sairaalahoitoista uloshengitysvaikeutta varhaislapsuudessa. Tutkittaville ja kahdelle kontrolliryhmälle lähetettiin kirjekysely, jossa kartoitettiin heidän astma, allergia ja hengitystieoireilua sekä tupakointia ja painotiedot. Vastauksien perusteella astma määriteltiin kahdella tavalla: lääkärin toteama astma ja kliininen astma.

Aikuisuudessa (kohortti 1981–1982) 20 % sairasti lääkärin toteamaa astmaa tai 41 % kliinistä astmaa. Vastaavat luvut kontrolliryhmissä olivat 5 % ja 10 %. Allerginen nuha ja tupakointi olivat yhteydessä astmaan, johon ylipaino ei näyttänyt vaikuttavan. Varhaislapsuuden uloshengitysvaikeus ja sairaalahoitoa vaatinut RSV infektiioivat itsenäisiä astman riskitekijöitä. Nuoruusiässä (kohortti 1992–1993) 30–64% tutkittavista oli astma tai kliininen astma. Vastaavat luvut kontrolliryhmässä olivat 5-11 %. Rhinoviruksen aiheuttaman alahengitystieinfektion sairastaneilla oli enemmän kliinistä astmaa (83 %) kuin RSV infektiion sairastaneilla (48 %). Ylipaino ei ollut yhteydessä astmaan, allergioihin eikä hengittävien kortikosteroidi lääkkeiden käyttöön. Atooppinen ihottuma varhaislapsuudessa ennusti astmaa nuoruusiässä.

Yhteenvedon voidaan todeta, että varhaislapsuudessa sairastettu uloshengitysvaikeus, mikä johtaa sairaalahoitoon lisää astmariskiä aikuisuudessa ainakin 27-vuoden ikään asti. Sairaalahoito RSV infektiio lisää astmariskiä nuoruus ja aikuisiässä ja rhinoviruksen aiheuttama alahengitystieinfektio lisää ainakin kliinisen astman riskiä nuoruusiässä. Ylipainolla ei ollut vaikutusta astmaan eikä allergioihin näillä tutkittavilla.

To Timo, Topi, Matias ja Lauri

Acknowledgements

This follow-up study was carried out in the Department of Pediatrics, Kuopio University Hospital, Finland during the years 1981-2008.

I want to express my gratitude and respect to Professor Raimo Voutilainen, M.D., Ph.D., Head of the Department of Pediatrics, University of Eastern Finland, Docent Mikko Perkkiö, M.D., Ph.D., and Docent Pekka Riikonen, M.D., Ph.D., Heads of the Department of Pediatrics, Kuopio University Hospital, for giving me the opportunity to initiate and carry out this study.

I feel myself privileged for having been able to undertake my thesis under the guidance of my principle supervisor Professor Matti Korppi, M.D., Ph.D. He is an amazing person as a scientist, clinician, teacher and a human being. His never ending encouragement and enthusiasm for scientific research have supported me and opened my eyes to the fascinating world of science during these years.

I want to express my warmest thanks to Eija Piippo-Savolainen, M.D., Ph.D., my second supervisor, for all her help and support during this project. She stimulated and motivated me to progress in the scientific world; it was and is still an exciting experience.

I am grateful to the official reviewers of this thesis, Professor Hannu Kankaanranta, M.D., Ph.D., and Docent Tuomas Jartti, M.D., Ph.D., for their constructive criticisms and comments which have certainly improved this thesis. I also wish to thank Ewen MacDonald, Pharm. D., for kindly performing the linguistic revision of my thesis.

I own my deepest thanks to Mari Ylinen, M.D., Ph.D., for her practical guidance, support and friendship during this study. Her encouragement at the beginning of the study was indispensable.

I also wish to express my thanks to Antti Saari, M.D., for his invaluable help with height and weight data and being such convivil company during these years as were all my other fellow researchers.

I express my sincere thanks Docent Sami Remes, M.D., Ph.D., and Liisa Kröger, M.D., Ph.D., for their help and support.

I am very thankful to Anneli Paloranta, research nurse, for her kind collaboration and skilful work during the study. Her sunny smile and kindness lit up also even the bad days.

I also want to thank all my colleagues in the Department of Pediatrics and Pediatric Neurology for their support and sympathy during this work.

I am very grateful to my fellow researchers; Ismo Makkonen, M.D., Ph.D., Pauliina Utriainen, M.D., Ph.D., Katri Backman, M.D., Eija Bergroth, M.D., Marjo Karvonen, M.D., Leena Kilpeläinen, M.D., Tanja Kuiri-Hänninen, M.D., Aino Mäntyselkä, M.D., Pauliina Nousiainen, M.D., Virpi Sidoroff, M.D. and Sanna Silvennoinen, M.D., for being such wonderful company. The lively conversation about science and many other things has been both very refreshing and relaxing; it has been pleasure to share time and thoughts with you.

I am thankful to Vesa Kiviniemi, Ph.Lic, for his advice on statistical problems.

I owe my special thanks to Mrs. Liisa Korkalainen, Mrs. Mirja Pirinen and Mrs Tiina Virolainen for their friendship and helpfulness in many practical problems.

My most sincere thanks belong to all the participants who have answered the questionnaire, and also to their parents. Without their positive attitude towards research, this study could never have been completed.

All my dear friends are warmly thanked for their delightful company and support.

I am grateful to my dear mother Sinikka Happonen for all the care and love she has given to me during my life. I also want to express my thanks to my brother Tuomo, for being a big brother at different points in my life.

Finally, no words can express the gratitude and love I feel for my family, especially my dear husband Timo. He has shared both the darkest and the brightest moments of the life and this work with me. Without his love, support and patience I would have never been able to finish this project. I also want to thank our sons, Topi, Matias and Lauri, for just being our children and thus making life worth of living.

This study was financially supported by Kerttu and Kalle Viik's Fund, the Foundation for Paediatric Research, National Graduate School of Clinical Investigation, Kuopio University Hospital and the University of Eastern Finland, which are sincerely acknowledged.

Kuopio, December 2013

Marja Ruotsalainen

List of the original publications

This dissertation is based on the following original publications:

- I Ruotsalainen M, Piippo-Savolainen E, Hyvärinen MK, Korppi M. Adulthood asthma after wheezing in infancy: A questionnaire study at 27 years of age. *Allergy* 65:503-509, 2010.
- II Ruotsalainen M, Piippo-Savolainen E, Hyvärinen MK, Korppi M. Respiratory morbidity in adulthood after RSV hospitalization in infancy. *Pediatr Infect Dis J* 29:872-874, 2010.
- III Ruotsalainen M, Sidoroff V, Piippo-Savolainen E, Hyvärinen MK, Korppi M. Association between overweight and asthma or allergy: Results from a prospective 27-year post-bronchiolitis follow-up. *Curr Pediatr Res* 16:95-100, 2012.
- IV Ruotsalainen M, Hyvärinen MK, Piippo-Savolainen E, Korppi M. Adolescent asthma after rhinovirus and respiratory syncytial virus bronchiolitis. *Pediatr Pulmonol* 48:633-639, 2013.
- V Ruotsalainen M, Hyvärinen MK, Saari A, Piippo-Savolainen E, Korppi M. No association between overweight and asthma or allergy in adolescence after wheezing in infancy. *Acta Paediatr* 102:167-171, 2013.

The publications were adapted with the permission of the copyright owners.

Contents

1 INTRODUCTION.....	1
2 REVIEW OF THE LITERATURE	3
2.1 Wheezing disorders and phenotypes in childhood	3
2.2 Respiratory viruses	4
2.2.1 Respiratory syncytial virus	4
2.2.2 Rhinovirus	4
2.3 Long-term outcome studies after hospitalization for bronchiolitis	5
2.3.1 Prospective birth cohort studies	5
2.3.2 Prospective post-bronchiolitis follow-up studies	5
2.3.3 Other long-term follow-up studies	7
2.4 Early-life predictive factors for long-term outcome after wheezing in infancy	8
2.4.1 Age	8
2.4.2 Viruses	8
2.4.3 Parental asthma and allergy.....	9
2.4.4 Eosinophilic inflammation	9
2.4.5 Early exposure to inhalant allergens	10
2.4.6 Tobacco smoke exposure	10
2.5 Asthma in adolescents and young adults.....	11
2.5.1 Prevalence	11
2.5.2 Diagnostics	11
2.5.3 Risk factors.....	12
2.5.4 Tobacco smoking	13
2.5.5 Role of overweight or obesity	13
3 AIMS OF THE STUDY	15
4 SUBJECTS AND METHODS	16
4.1 Baseline data on study group 1981-1982	16
4.1.1 Study subjects	16
4.1.2 Collection of baseline data	17
4.1.3 Laboratory tests and early-life data on allergy	17
4.1.4 Previous follow-up of the cohort.....	18
4.2 Baseline data on study group 1992-1993	18
4.2.1 Study subjects	18
4.2.2 Collection of baseline data	19
4.2.3 Laboratory tests	19
4.2.4 Previous follow-up of the cohort.....	20
4.3 Control subjects	20
4.4 Questionnaire follow-up in 2008	21
4.4.1 Study subjects in Group 1981-1982	21

4.4.2 Study subjects in Group 1992-1993	21
4.4.3 Control subjects	21
4.4.4 Posted questionnaire	22
4.4.5 Definition of asthma	22
4.4.6 Definition of allergy	22
4.4.7 Definition of overweight and obesity	22
4.5 Statistical analyses.....	23
4.6 Ethics	23
5 RESULTS	24
5.1 Outcomes in adulthood after wheezing in infancy (Group 1981-82)	24
5.1.1 Prevalence of asthma and wheezing symptoms (I, II)	24
5.1.2 Early predictive factors for adulthood asthma (I)	26
5.1.3 Comparison between RSV and non-RSV bronchiolitis ...	26
5.1.4 Overweight or obesity (III)	26
5.2 Outcome in adolescence after wheezing in infancy (Group 1992-93)	28
5.2.1 Prevalence of asthma and wheezing symptoms (IV)	28
5.2.2 Early predictive factors for adolescence asthma (IV)	28
5.2.3 Comparison between RSV and non-RSV bronchiolitis ...	29
5.2.4 Overweight or obesity (V).....	30
6 DISCUSSION	32
6.1 Design of the study	32
6.2 Prevalence of asthma and wheezing symptoms	32
6.3 Outcome in relation to viral etiology of bronchiolitis and early-life risk factors	34
6.4 Outcome in relation to overweight or obesity	35
6.5 Methodological aspects	36
6.5.1 Strengths of the study	36
6.5.2 Shortcomings of the study	37
7 CONCLUSION	39
8 REFERENCES	40
APPENDICES: KYSELYLOMAKE	
ORIGINAL PUBLICATIONS I-V	

Abbreviations

AOR	Adjusted odds ratio
AD	Atopic dermatitis
B-Eos	Blood eosinophils
BMI	Body mass index
BMI-SDS	BMI-standard deviation score
CI	Confidence interval
COPD	Chronic obstructive pulmonary disease
ECP	Eosinophil cation protein
ECT	Exercise challenge test
FVC	Forced vital capacity
FEV1	Forced expiratory volume in one second
FVS	Flow volume spirometry
HRV	Human rhinovirus
HMPV	Human metapneumovirus
IFN- γ	Interferon- γ
IgE	Immunoglobulin E
LRI	Low respiratory infection
NPA	Nasopharyngeal aspirate
OR	Odds ratio
PCR	Polymerase chain reaction
PEF	Peak expiratory flow
RSV	Respiratory syncytial virus
SPT	Skin prick test
Th-cell	T-helper cell

1 Introduction

Wheezing in early childhood is a heterogeneous condition; it is rather common in infants and young children with respiratory infection. More than one in every three children will suffer from wheezing by the age of three years (Martinez et al. 1995, Taussig et al. 2003, Illi et al. 2004) and 2% percent of all infants suffer from wheezing severe enough to require hospitalization (Korppi et al. 1986, Boyce et al. 2000, Koehoorn et al. 2008). Bronchiolitis is usually defined as the first wheezing episode in infancy, but there is no global consensus about other criteria such as clinical features, viral findings, or exact age limits. The long-term prognosis varies: some children may become completely symptom-free other develop chronic asthma and suffer reduced lung function continuing until adulthood as documented in two prospective birth cohort studies (Larouche et al. 2000, Stern et al. 2007, Stern et al. 2008), and in two prospective post-bronchiolitis follow-up studies (Piippo-Savolainen et al. 2004, Korppi et al. 2004, Goksör et al. 2006, Goksör et al. 2007, Goksör et al. 2008), and in one respiratory syncytial virus (RSV) bronchiolitis follow-up study (Sigurs et al. 2010).

Nearly all children have experienced at least one RSV infection by the age of two years, and 0.5 – 2.0 % of them require hospitalization due to this infection. Severe RSV infection is a leading cause of hospitalization in infants in both the industrialized and the developing nations (Kneyber et al. 2000). There are also other viruses, e.g. rhinovirus, human metapneumovirus, and human bocavirus, which can trigger bronchiolitis needing hospitalization. In particular rhinovirus has been associated with wheezing episodes in infancy (Jartti et al. 2004a, Kotaniemi-Syrjänen et al. 2003, Jackson et al. 2008, Busse et al. 2010, Jartti and Korppi 2011), with subsequent wheezing and asthma at preschool age (Jackson et al. 2008), and even with asthma and bronchial hyper-responsiveness at school age (Kotaniemi-Syrjänen et al. 2003, Hyvärinen et al. 2005b).

A number of studies have evaluated genetic and early life factors which can influence the risk of asthma and allergy. A family history of asthma has been associated with recurrent wheezing and persistence of asthma into childhood (Martinez et al. 1995, Carroll et al. 2007, Lim et al. 2009, Jartti et al. 2009a, Carroll et al. 2012) and also in adulthood (Piippo-Savolainen et al. 2006). Blood eosinophilia has been found in association with RSV and rhinovirus bronchiolitis in several studies (Wennergren et al. 1997, Ehlenfield et al. 2000, Kim et al. 2003, Jartti et al. 2006, Piippo-Savolainen et al. 2007a, Hyvärinen et al. 2010). The presence of atopic dermatitis (AD) and atopic sensitization in infants are factors predicting childhood asthma until school age (Castro-Rodriguez et al. 2000, Taussig et al. 2003, Morgan et al. 2005, Hyvärinen et al. 2005b), particularly if the child has suffered from wheezing already in early life. Eosinophilic inflammation is a typical finding in asthma, thus, it has been a subject of interest to determine whether eosinophilia during bronchiolitis would be a risk factor for later asthma. The results of the studies have been conflicting. Similarly, the influence of early exposure to inhalant allergens to the risk of later asthma is also unresolved. In Multicentre Allergy Study (MAS) from Germany, an exposure to indoor allergens in early life was associated with wheezing symptoms in their teenage years (Matricardi et al. 2008). In Finnish bronchiolitis studies, an exposure to indoor allergens in early life increased the risk for asthma until the teenage years, but no longer in adulthood (Hyvärinen et al. 2005a, Hyvärinen et al. 2005b, Piippo-Savolainen et al. 2006). Exposure to tobacco smoke both during pregnancy, in infancy and in childhood has increased the risk of wheezing and asthma in several studies (Stein et al. 1999, Taussig et al. 2003, Lannerö et al. 2006, Goksör et al. 2007). Furthermore active smoking in adolescence and adulthood also increases the risk of current asthma (Strachan et al. 1996, Sears et al. 2003).

Asthma and obesity have been linked together. The prevalence of overweight and obesity among children and young adults has increased in epidemic proportions in western countries concomitantly with the asthma and allergy epidemics (Ford 2005, Flaherman and Rutherford 2006). Epidemiological studies have shown a modest association between overweight or obesity and the prevalence of asthma in adults (Ford 2005, Hancox et al. 2005, Jarthi et al. 2009) but investigations in children have given conflicting results (To et al. 2004, Guerra et al. 2004, Vignolo et al. 2005, Flaherman and Rutherford 2006, Mannino et al. 2006, Mamun et al. 2007, Del Rio-Navarro et al. 2013). At least in adults, obesity-related asthma seems to be a disfned asthma phenotype not showing any association with eosinophilic inflammation in the airways (Lugugo et al. 2010). The association between weight status and allergy is less studied. Many authors have not shown the association between overweight and allergic diseases or atopic sensitization (Jarvis et al. 2002, Ma et al. 2010) or opposite to the expectations, underweight has been associated with atopic sensitization (Van Glysel et al. 2009) and allergic rhinitis (Silverberg et al. 2011) at school age. However, overweight has been associated with atopic dermatitis (Silverberg et al. 2011, Kusunoki et al. 2008) and food allergies in teenager (Visness et al. 2009).

The main aim of this thesis was to examine, if early-life risk factors exert any influence on the risk of later allergy or asthma after hospitalization for wheezing in infancy, if former bronchiolitis patients carry a higher asthma risk in adolescence and adulthood compared with population controls and if overweight or obesity has an association with asthma or allergy in later life after wheezing in infancy.

2 Review of the Literature

2.1 WHEEZING DISORDERS AND PHENOTYPES IN CHILDHOOD

Wheezing children form a heterogeneous group with different genotypes and phenotypes leading to different outcomes. One out of every three children has at least one episode of wheezing prior to their third birthday, and the cumulative prevalence of wheeze is almost 50% at the age of six years (Martinez et al. 1995, Bisgaard et al. 2007). Some of the children become symptom free, while others develop allergies and asthma as they grow up (Wennergren et al. 1997, Taussig et al. 2003, Piippo-Savolainen et al 2004).

Bronchiolitis is one of the most common viral infectious respiratory conditions of early childhood and the leading cause of hospitalization of infants (Boyce et al. 2000, Carroll et al. 2008). It is characterized by acute inflammation, edema and necrosis of epithelial cells lining small airways, increased mucus production and bronchospasm. Cellular debris, inflammatory cells and fibrin cause airway obstruction. Mucus plugs can partly or totally occlude the bronchioli, causing diffuse air trapping or atelectasis. It is usually defined as the first wheezing episode in infancy, but there is no global consensus on the other criteria such as clinical features, viral findings or age limits. The American Academy of Pediatrics (AAP) has proposed an upper age limit of 24 months (American Academy of Pediatrics 2006), but both 24 months (Piippo-Savolainen et al. 2004, Goksör E et al. 2006, Piippo-Savolainen and Korppi 2009) and 12 months (Piippo-Savolainen and Korppi 2009, Sigurs et al. 2010) have been used in different studies. About 2 % of all infants suffer from bronchiolitis severe enough to warrant hospitalization (Boyce et al. 2000, Kneyber et al 2000, Koehoorn et al. 2007).

There are two main classifications of the phenotypes of early childhood wheezing that have been used to evaluate and predict asthma and allergy symptoms in school age and later in adulthood. The first was based on onset and duration of wheezing. For example, this was applied in the Tucson birth cohort study, the wheezing children could be classified into three main phenotypes: transient early wheezers (wheezing before the age of three years but not at six years of age), persistent wheezers (wheezing both before the age of three years and at six years of age) and late-onset wheezers (no wheezing before three years of age, but wheezing at six years of age) (Taussig et al. 2003, Morgan et al. 2005). Early transient wheezers form the majority, 60%, of all early-childhood wheezers, and display wheezing symptoms only during respiratory infections (Taussig et al. 2003). About half of the rest of the wheezers become sensitized to inhalant allergens before school age, and in terms of sensitization, they are classified into atopic and non-atopic wheezers (Sherrill et al. 1999, Taussig et al. 2003).

In the report of Task Force of the European Respiratory Society (ERS) it was recommended that the definition of the phenotypes of early childhood wheezing should be based on the temporal pattern of wheezing symptoms (Brand et al. 2008). Children with intermittent wheezing associated with clinical evidence of the viral respiratory tract infection, with no wheezing symptoms in between, were classified as having episodic viral wheeze. Children with wheezing symptoms that exhibit discrete exacerbations, but also experience symptoms between episodes, were classified as having multiple-trigger wheeze (Brand et al. 2008). Episodic viral wheeze was proposed to be the type with less risk of developing subsequent asthma (Brand et al. 2008), while multiple-trigger wheezers are believed to reflect chronic airway inflammation with an increased risk of developing allergic asthma (Brand et al. 2008, Sonnappa et al. 2010). Some researchers have criticized this classification claiming that it is more a marker of severity rather than a definition of wheezing phenotype (Garcia-Marcos and Martinez 2010).

Subsequently, obesity-related asthma has been suggested as its own asthma phenotype for both adults (Lessard et al. 2008, Lang et al. 2011, Wenzel 2013) and children (Jensen et al. 2011). In children, the lung function disorders seems to start at 6-11 years of age with symptoms appearing at 12-17 years of age (Lang et al. 2011), but not being associated with atopy (von Mutius et al. 2001).

In addition to the phenotypes of wheezing and asthma, some investigators have proposed that there are also asthma endotypes, such as allergic asthma, preschool wheezers with positive asthma-predictive indices, late-onset hypereosinophilic asthma, noneosinophilic asthma, elite-athlete asthma, infection-induced asthma and airflow obstruction caused by obesity. These are thus different forms of classification from phenotypes which describe distinct disease entities with defining etiologies and characteristic pathophysiological mechanisms (Lötvall et al. 2011)

2.2 RESPIRATORY VIRUSES

Respiratory syncytial virus is the predominant wheezing-associated virus in < 12 months old infants whereas rhinovirus prevalence increases with age (Rakes et al. 1999, Jartti et al. 2009, Sigurs et al. 2010, Jartti and Korppi 2011, Mansbach et al. 2012). Metapneumovirus seems to be the third in the order in < 12 months (Wolf et al. 2006) and bocavirus in 13-24 months old children (Allander et al. 2007). In addition, influenza A and B viruses, parainfluenza viruses (types 1-4), adenovirus, coronavirus and enterovirus are significant pathogens causing respiratory tract infections (Mahony 2008, Brand et al. 2012).

2.2.1 Respiratory syncytial virus

The primary RSV infection occurs at six weeks to two years of age, and is usually symptomatic involving the lower respiratory tract and presenting with wheezing, atelectasis and pneumonia. Subsequent infections, usually limited to the upper airways, are common (Ogra 2004). By two years of age, 80% to 90% of all children have experienced at least one RSV infection and 0.5% to 2.0% have needed to be treated in hospital (Kneyber et al. 2000).

Most RSV infections occur between late fall and early spring with a peak prevalence in winter (Hall et al. 2001, Smyth 2007). In Finland, RSV epidemics have occurred in two-year cycles, with a minor epidemic in the spring preceding the major epidemic in the autumn (Jartti et al. 2004b).

2.2.2 Rhinovirus

There are more than 100 serotypes and more than 150 genotypes of human rhinoviruses (HRV) (Heymann et al. 2005, Lee et al. 2007, Mahony 2008, Lee et al. 2012). The species can be classified as HRV-A, HRV-B or HRV-C viruses based upon genetic homology (Peltola et al. 2008, Jartti et al. 2008, Lee et al. 2012). In a recent study, patients with asthma exacerbations more often had HRV-C, and HRV-C infection was associated with more severe disease (Bizzintino et al. 2011).

Rhinovirus infections occur all year round, with peaks in late spring and early fall and are responsible for two-thirds of cases of the common cold outside RSV seasons, and these are associated with wheezing and asthma exacerbations from the age of 12 months onward (Lemanske 2002, Lemanske et al. 2005, Kusel et al. 2007, Jackson et al. 2008, Midulla et al. 2012).

HRV-induced wheezing episodes in infancy have been identified as an important predictor of recurrent wheezing and childhood asthma in several studies (Kotaniemi-Syrjänen et al. 2003, Lemanske et al. 2005, Lehtinen et al. 2007, Kusel et al. 2007).

2.3 LONG-TERM OUTCOME STUDIES AFTER HOSPITALIZATION FOR BRONCHIOLITIS

There are numerous retrospective and prospective cohort studies investigating the outcome of childhood wheezing and on the development and prevalence of asthma and allergy in childhood. Whether the association between bronchiolitis and subsequent asthma is due to causality or a reflection of predisposition may be dependent on host factors and virus-specific effects. This review only includes studies on bronchiolitis severe enough to require hospital care with a follow-up of the patients until adulthood.

2.3.1 Prospective birth cohort studies

The Tucson Children's Respiratory Study is thus far the only prospective birth cohort study (Taussig et al. 1989). That study began in 1980, and in all, 1246 subjects have been followed from birth to adulthood. The basic information has been collected by questionnaires and lung function measurements, skin prick tests (SPT) and also laboratory determinations have been concluded at the follow-up visits. Data was also collected during lower respiratory infection (LRI) in the first three years of life. The study has facilitated the assessment of the natural history and outcome of acute LRI in young children, and the development and risk factors of chronic lung disorders, especially asthma, and atopy later in life (Taussig et al. 2003).

In the Tucson cohort, the prevalences of wheezing associated with respiratory infection were 32.0%, 17.3% and 12.0% during the first, second, and third years of life, respectively (Taussig et al. 2003). RSV infection in early childhood seemed to be an independent risk factor for subsequent wheezing and the development of asthma up to age 11 years but not at age 13 (Stein et al. 1999). If the lung function measured in infancy was in the lowest quartile, the values for forced expiratory volume in one second (FEV₁) / forced vital capacity (FVC) ratio, and FEV₁, remained reduced up to age 22 years (Stern et al. 2007).

More than 80% of children who wheezed during the first year of life were transient wheezers (Taussig et al. 2003). One important finding emerging from the Tucson Children's Respiratory Study was that these children had lower lung function at birth which improved with time but did not "catch up" with those of children who never wheezed during their growing years (Taussig et al. 2003). Most children who will go on to develop atopic asthma in later life experience their first wheezing symptoms during the first six years of life (Taussig et al. 2003). Sensitization against *Alternaria alternata* showed the strongest association with this form of wheezing (Halonen et al. 1999) and was associated with later physician-diagnosed asthma (Taussig et al. 2003).

The Tucson Children's Respiratory Study identified the phenotypes of early childhood wheezing and their different outcomes, and the prevalence of active asthma diagnosed by a physician increased at each survey until age 16 years (Taussig et al. 2003, Morgan et al. 2005). From 16 to 22 years of age, the incidence of asthma was 12.6 per thousand person-years, 27% asthma cases were new and 73% were chronic or relapsed asthma cases (Stern et al. 2008). Bronchial hyper-responsiveness, low lung function at six years, and late-onset and persisting wheezing predicted newly diagnosed asthma at age 22 years (Stern et al. 2008).

2.3.2 Prospective post-bronchiolitis studies

Children with wheezing severe enough to need hospital treatment at less than 24 months of age represent a group at particular risk for developing asthma and other respiratory disorders in later life (Piippo-Savolainen and Korppi 2008). There are only three prospective follow-up studies after hospitalization for bronchiolitis (Table 1), one from Finland and two from Sweden, which have continued up to adolescence even to adulthood (Korppi et al. 1986, Wennergren et al. 1992, Sigurs et al. 1995, Wennergren et al. 1997, Sigurs

et al. 2000, Piippo-Savolainen et al. 2004, Hyvärinen et al. 2005a, Sigurs et al. 2005, Goksör et al. 2006, Sigurs et al. 2010).

Sigurs et al. examined RSV bronchiolitis patients, and age- and gender-matched controls, on admission and at later control visits (Sigurs et al. 1995, Sigurs et al. 2000, Sigurs et al. 2005, Sigurs et al. 2010). At the early adulthood control visit, the research protocol included a questionnaire, clinical examination, SPT, lung function measurements, analyses for serum IgE antibodies to inhaled allergens and blood eosinophil count. The prevalence of asthma and/or recurrent wheezing (39% vs. 9%), and that of atopic sensitization (30% vs. 1%), were still present at the median age of 18 years (Sigurs et al. 2010). In the former RSV group, lung functions were reduced in comparison with controls irrespective of the presence of asthma (Sigurs et al. 2010). Thus, hospitalization for early-life RSV bronchiolitis was associated with an increased prevalence of allergic asthma into early adulthood (Sigurs et al. 2010).

The other Swedish prospective post-bronchiolitis study included children hospitalized for wheezing before two years of age and age-matched controls with later follow-up visits (Wennergren et al. 1992, Wennergren et al. 1997, Goksör et al. 2006). The research protocol included a questionnaire, clinical examinations, SPT, lung function measurements, and determination of serum IgE antibodies to inhaled allergen and of blood eosinophils at 17 - 20 years of age (Goksör et al. 2006). In the former bronchiolitis group, the prevalence of asthma was 43 % vs. 15 % in the age-matched control group, and a family history of atopy, tobacco smoke exposure in infancy, and female gender were the significant early-life risk factors of asthma in early adulthood (Goksör et al. 2006). Lung functions were reduced in the early life children with acute wheezing, especially in females with current asthma, compared with age-matched controls (Goksör et al. 2008). Current allergy was strongly associated with current asthma in the bronchiolitis cohort (Goksör et al. 2006).

In the present Finnish post-bronchiolitis cohort, the children were also under two years of age on admission for bronchiolitis (Korppi 1986). The control group consisted of infants without a family history of atopy, and with no history of wheezing symptoms in infancy (Pöysä et al. 1988), and both groups were followed-up (Korppi et al. 1993, Kuikka et al. 1994, Korppi et al. 1994, Hyvärinen et al. 2005a, Piippo-Savolainen et al. 2004). Asthmatic and atopic symptoms were screened by a written questionnaire at the median age of 14.9 years and current asthma was present in 14% in the bronchiolitis group (Hyvärinen et al. 2005a). There were three early asthma-predictive factors which could be identified in infancy wheezing, atopic dermatitis and elevated blood eosinophil numbers (Hyvärinen et al. 2005). The research protocol included a questionnaire, clinical examinations, SPT, and lung function measurements in the early adulthood control visit (Piippo-Savolainen et al. 2004). At the median age 19 years, asthma was present in 30% of the former bronchiolitis group vs. 11 % in the control group (Piippo-Savolainen et al. 2004a). Atopy was seen to be an independent risk factor for asthma. Lung functions were normal both in the former bronchiolitis group and in the control group, however, abnormal values in flow volume spirometry (FVS) were more common in the bronchiolitis group (Piippo-Savolainen et al. 2004). In early adulthood, the early asthma-predictive factors were parental asthma and repeated wheezing (Piippo-Savolainen et al. 2006), but eosinophilia did not predict wheezing or asthma in adulthood (Piippo-Savolainen et al. 2007a).

Table 1. Overview of prospective post-bronchiolitis studies

	Starting time	Bronchiolitis patients (N)	Control group (N)	Age at inclusion	Control visits	Viruses studied (RSV %)
Sigurs	1989-90	47	93	< 12 months (mean 116 days)	1y, 3y, 7.5y, 13.4y, 18y (mean)	RSV only (100%)
			Age and gender matched, no early RSV			
Wennergren, Goksör	1984-85	101	294	< 24 months (median 10 months)	3-4.5y, 10y, 17-20y	6 (50%)
Korppi, Piippo-Savolainen	1981-82	83	72	< 24 months (median 10 months)	2-3y, 4.4-6y, 8-10y, 14.9y, 18-21y	7 (40%)
			No atopic heredity, no wheeze < 2y			

y = year

2.3.3 Other long-term follow-up studies

In Canada, 42 subjects aged 17-35 years with a past history of hospitalization for bronchiolitis in the first 18 months of life and 42 controls, were evaluated (Larouche et al. 2000). The study included SPTs, flow-volume spirometry, metacholine challenge test, blood samples and a detailed questionnaire. In the group with past bronchiolitis, there was an elevated risk for asthma, airway hyperresponsiveness was increased, and the ventilation functions (FEV₁, FEV₁ / FVC) were lower. There were no significant differences between the groups in terms of atopy, blood eosinophil count or IgE level (Larouche et al. 2000).

In Spain, 71 subjects aged 19 - 24 years with a history of viral bronchiolitis in infancy and 32 controls, were evaluated (Gómez et al. 2004). The study included SPTs, FVS, and metacholine challenge test. The bronchiolitis group had a higher prevalence of respiratory symptoms and bronchial hyperresponsiveness than controls. FVS, expect peak expiratory flow (PEF), and SPT responses did not differ between the groups (Gómez et al. 2004).

2.4 EARLY-LIFE PREDICTIVE FACTORS FOR LONG-TERM OUTCOME AFTER WHEEZING IN INFANCY

There are numerous reports describing the risk factors for subsequent wheezing and later asthma in children with bronchiolitis in infancy. In this review, only the most commonly reported in long-term studies until adolescence or adulthood have been included.

2.4.1 Age

The immune system in infancy is different than the immune system in later childhood and in adulthood. Though innate immunity is working adequately, the lack of prior exposure to pathogens means that there is a deficient immune memory. This has a critical impact on susceptibility to respiratory viral infection (Adkins et al. 2004). Age under six months predicts the need for hospital care and severe bronchiolitis which is, at least partly, attributable to immature immunity (Voets et al. 2006, Mansbach et al. 2012). Severe RSV infection in infancy is a risk factor for both recurrent wheezing and asthma until school age, showing a decreasing impact with age (Régnier and Huels 2013), and the risk may continue into the teenage years (Sigurs et al. 2005). On the other hand, the risk of post-bronchiolitis asthma seems to be higher, if wheezing starts after 12 months of age, and especially, if there is repeated wheezing in the period 1 – 3 years of age (Taussig et al. 2003, Jackson et al. 2008, Piippo-Savolainen and Korppi 2008). Age and number of previous wheezing episodes are linked to inflammatory and virologic risk factors of asthma (Jartti et al. 2009).

2.4.2 Viruses

Respiratory viral infection works together with allergy to produce inflammatory changes and even damage to the immune system in the airways necessary for triggering asthma (Busse et al. 2010, Callaway and Kim 2011). The timing of the birth in relation to the winter virus peak, especially RSV peaks, may impact on asthma development. An increased risk was found among children aged four months during the winter virus peak (Wu et al. 2008). The rural question as to whether this is primarily a viral or a host-response effect has not been resolved (Jackson et al. 2010, Zhang et al. 2009).

In infants, RSV bronchiolitis displays many similarities with acute asthma: small airway inflammation, rapid breathing to compensate for the hypoxemia, often wheezing, and sometimes airway complications (Hall et al. 2009). The risk of developing chronic respiratory conditions, including asthma, is elevated among those hospitalized for RSV infection in infancy (Sigurs et al. 2005, Korppi et al. 2004, Henderson et al. 2005, Sigurs et al. 2010) and that increased risk may persist into adulthood (Sigurs et al. 2010). In a Danish twin registry study, however, it was claimed that severe RSV infection in infancy did not cause asthma, but asthma was merely due to a genetic predisposition forwards asthma (Thomsen et al. 2009).

HRV has been recognized as an important risk factor for asthma among young wheezing children (Kotaniemi-Syrjänen et al. 2003, Lemanske et al. 2005, Lehtinen et al. 2007, Kusel et al. 2007, Jackson et al. 2008, Carroll et al. 2008, Jartti and Korppi 2011, Lukkarinen et al. 2013). Recent studies have identified that lower respiratory HRV infection could lead to airway damage and remodeling and later on the development of asthma (Jackson 2010). It has been appeared that the age at which HRV illnesses occurred had significant prognostic value with regarded to the subsequent risk of asthma. Wheezing with HRV infection during the first three years of life was associated with a dramatic increase in the risk of asthma at school age (Jackson 2010). Wheezing associated with HRV, even cases representing the first wheezing episode, may be the first sign of childhood asthma (Kotaniemi-Syrjänen et al. 2003). HRV bronchiolitis has been linked also to atopy-related factors (Rakes et al. 1999, Korppi et al. 2004, Jartti et al. 2006, Kusel et al. 2007). Thus, the final roles of the host and viral factors are thus far unresolved.

2.4.3 Parental asthma and allergy

A family history of asthma has been associated with the severity or incidence of bronchiolitis during infancy and with the risk of asthma in childhood (Martinez et al. 1995, Carroll et al. 2007, Lim et al. 2009, Carroll et al. 2012, Bacharier et al. 2012). Delayed immune maturation at birth, as indicated by blood cytokine levels or responses to stimulation *in vitro*, has been detected in infants born to parents with allergy or asthma (Sly and Holt 2011). In the Swedish follow-up after RSV bronchiolitis in infancy, parental asthma was a risk factor for current asthma and recurrent wheezing symptoms over 18 years after hospitalization (Sigurs et al. 2010). In a Finnish follow-up study parental asthma predicted adulthood asthma after wheezing in infancy (Piippo-Savolainen et al. 2006). Recurrent wheezers tended to have more often parents with asthma than first-time wheezers (Jartti et al. 2009). In some studies, maternal asthma has had a greater impact for the asthma risk of their children than whose fathers are asthmatics (Lim et al. 2010, Bacharier et al. 2012).

A family history of allergy, if the parents are not asthmatic, has not been associated with the severity of bronchiolitis (Just et al. 2010, Semple et al. 2011). However, in a Norwegian study, parental atopy predicted asthma at 11 years of age if the child had experienced recurrent wheezing in infancy (Mikalsen et al. 2013). The German Multicentre Allergy Study is a birth cohort follow-up which has evaluated the relationship of early atopic sensitization and a family history of atopy with subsequent wheezing symptoms (Matricardi et al. 2008). In that study, family history of atopy was a strong risk factor for persisting wheezing at 11-13 years of age. The Swedish study identified chain of links starting from atopy in family members to the development of atopy and further to the development of adulthood asthma after early childhood wheezing (Goksör et al. 2006).

2.4.4 Eosinophilic inflammation

A number of studies have demonstrated eosinophilia during or after RSV and/or HRV bronchiolitis (Wennergren et al. 1997, Ehlenfield et al. 2000, Kim et al. 2003, Piippo-Savolainen et al. 2007a, Hyvärinen et al. 2010). Eosinophilia has been higher during HRV than RSV infections. The results of different studies, however, have been conflicting. In a Swedish study, no association was found between eosinophilia during bronchiolitis and and persistent asthma at 10 years of age (Wennergren et al. 1997). In another study, blood eosinophilia at the time of bronchiolitis predicted the development of persisting wheezing at seven years of age (Ehlenfield et al. 2000). In Finnish studies, eosinophilia during bronchiolitis was not associated with wheezing symptoms or asthma in later life (Piippo-Savolainen et al. 2007a, Hyvärinen et al. 2010), but elevated levels of eosinophils during convalescence predicted an increased asthma risk until preschool and early school years although no longer thereafter (Piippo-Savolainen et al. 2007a). Even more than viral effects, eosinophilia in early infancy may reflect the Th2-oriented imbalance and allergic sensitization occurring during pregnancy or during infancy (Frischer et al. 2000).

A French cohort study reported that eosinophilia was an important biological variable associated with the persistence of asthma and the lack of eosinophilia predicted the future remission of wheezing symptoms at the age of six years after experiencing wheezing in infancy (Just et al. 2008, Just et al. 2010). Similarly, eosinophilia greater than 4 % under the age of three years was a significant predictor of persistent wheezing in the Tucson birth cohort, and even more clearly, repeatedly measured low eosinophilia counts less than 2 % predicted the absence of asthma and wheezing at school age (Karakoc et al. 2002).

Eosinophil cationic protein (ECP) is a mediator, which activated eosinophil release from their granules. Elevated levels of nasopharyngeal aspirate (NPA) ECP have predicted subsequent wheezing (Reijonen et al. 1997) and were considered to be a risk factor for persistent childhood asthma (Hyvärinen et al. 2010). However elevated blood ECP concentration during bronchiolitis exerted no influence on the future risk of wheezing symptoms or asthma (Wennergren et al. 1997, Rakes et al. 1999, Hyvärinen et al. 2010).

2.4.5 Early exposure to inhalant allergens

Over twenty years ago David Strachan first postulated the so-called hygiene hypothesis where infections in early childhood might prevent the development of allergic diseases later in life (Strachan 1989). Subsequently, a lifestyle with early exposure to allergens, such as living in a farm, has appeared to prevent later asthma and allergy (Braun-Fahrlander et al. 2002, Ege et al. 2011, Michel et al. 2013, MacNeill et al. 2013). Later, epidemiological studies have demonstrated that IgE-mediated sensitization to inhalant allergens is an important risk factor for asthma, particularly in childhood living in the developed countries (Custovic et al. 2010). The severity of asthma increases among atopic patients exposed to high levels of sensitizing allergen and the synergism between high allergen exposure and respiratory virus infection increases the risk of asthma exacerbation (Custovic and Simpson 2012).

Aeroallergen sensitization develops slowly and it does not offer much help in the early identification of high risk children. In infants aged < 12 months one cannot determine any aeroallergen sensitization in children with recurrent wheezing episodes. In children aged < 24 months and < 36 months, the figures were 13% and 16%, respectively (Jartti et al. 2009a). Nonetheless if there is sensitization to perennial allergens during the first three years of life, there is an association with a loss of lung function at school age (Illi et al. 2006). In the Prevention and Incidence of Asthma and Mite Allergy study, early house dust mite and cat allergen exposure often led to sensitization, and cat allergen sensitization further led to persistent wheeze at four years of age (Brussee et al. 2005). In the German birth cohort Multicentre Allergy Study, wheezing at the age of 13 years was associated with exposure to high levels of indoor allergens during early life and IgE sensitization to common allergens (Matricardi et al. 2008). In Finnish bronchiolitis cohorts, early allergy, especially sensitization to inhaled allergens, was a significant risk factor for asthma until teenage, but no longer in adulthood (Hyvärinen et al. 2005a, Hyvärinen et al. 2005b, Piippo-Savolainen et al. 2007c).

Some studies have reported that high exposure to cat allergen can protect against cat sensitization (Platts-Mills et al. 2001, Simpson et al. 2003). In line with hygienic hypothesis the GABRIEL project in Poland and Alpine regions of Germany, Austria and Switzerland showed that children living on a farm were at significantly reduced risk of suffering asthma, hay fever, atopic dermatitis and atopic sensitization compared with nonfarm children (Illi et al. 2012). Consequently no evidence-based recommendations on allergen avoidance as a means of preventing allergic disease can be provided (Custovic and Simpson 2012).

2.4.6 Tobacco smoke exposure

Tobacco smoke is the most common and important indoor environmental pollutant to which infants and young children are exposed. Several epidemiological studies have recognized an association between parental smoking and acute lower respiratory infections in children. Maternal smoking during pregnancy and other types of environmental tobacco smoke exposure have been associated with bronchiolitis severity and later asthma (Stein et al. 1999, Lannerö et al. 2006, Semple et al. 2011, Singh et al. 2011). After hospitalization due to early wheezing, pre- and post-natal smoke exposure was reported to increase the risk of asthma in early adulthood (Goksör et al. 2007). The Australian birth cohort study noted an association with wheezing symptoms and active smoking among those with reduced lung function in infancy (Mullane et al. 2013). In Finnish bronchiolitis follow-up studies, however, the association between tobacco smoke exposure and asthma has not been found, but maternal smoking at 0-2 years of age of the children was a significant risk factor for lung function abnormalities in adulthood (Piippo-Savolainen et al. 2006). A recent review article stated that exposure to prenatal and passive smoking increased the incidence of wheezing and asthma in children and young people by at least 20% with the most intense

effect from prenatal maternal smoking on asthma being detected in children aged less than two years (Burke et al. 2012).

Exposure to environmental tobacco smoke in early infancy has been reported to increase the risk of IgE sensitization to indoor inhalant and food allergens (Lannerö et al. 2008), and this may be the link between passive smoking, allergy and asthma.

2.5 ASTHMA IN ADOLESCENTS AND YOUNG ADULTS

Asthma is an inflammatory disease of the lower airways. Typical symptoms of asthma are cough, wheezing and shortness of breath. Asthma is diagnosed based on measurements of pulmonary function revealing variable or reversible airways obstruction.

2.5.1 Prevalence

Asthma is a serious public health problem throughout the world, affecting people of all ages (Global Initiative for Asthma, 2012). In last decades, the prevalence of asthma has increased significantly in most western countries, with a similar trend also apparent in low and middle incomes countries (Eder et al. 2006). The World Health Survey evaluated the global prevalence of asthma in adults in 70 countries using a questionnaire related to asthma diagnosis and respiratory symptoms (To et al. 2012). The prevalence of doctor-diagnosed asthma varied extensively between the participating countries, ranging from 0.2 % in China to 21.0 % in Australia, with the global prevalence of doctor-diagnosed asthma estimated at 4.3 %. The global prevalence of self-reported asthma including wheezing symptoms was 8.3 % (To et al. 2012). In a recent Swedish study the prevalence of doctor diagnosed asthma was 9.5 % in the adolescent age group of 16 to 20 years of age (Wennergren et al. 2010). In a recent epidemiological, population-based study in Finland the prevalence of asthma in the Finnish 16-year old population was 3 % (Huurre et al. 2004), with a reported prevalence of 4 % in adulthood (Pallasaho et al. 2011).

2.5.2 Diagnostics

Asthma is a chronic inflammatory disorder of the airways. This airway inflammation may be associated with variable changes in airway hyperresponsiveness, airflow limitation, respiratory symptoms and disease chronicity. The development of airflow limitation is the result of bronchoconstriction, airway edema and mucus secretion. It is recognized that airway remodeling, characterized by thickening of the wall, can exert profound consequences on the mechanics of airway narrowing and contribute to the chronic progression of the disease. Asthma is classically recognized as the typical Th 2 disease, with increased IgE levels and eosinophilic inflammation in the airway, but much work still needs to be done before it will be possible to understand in detail the different phenotypes of asthma (Lemaske et al. 2003, Kudo et al. 2013, Martinez and Vercelli 2013).

It is necessary to carry out measurements of pulmonary function to come to a diagnosis of asthma and these parameters are also useful for monitoring the course of asthma and the patient's response to therapy. Abnormalities in pulmonary function provide measures of the degree of airflow obstruction, and reflect the consequence of asthma on airway mechanics. In asthma, these pulmonary function abnormalities are reversible.

Measurement of peak expiratory flow (PEF) at home by using the peak flow meter can be an important aid in both diagnosis and monitoring of asthma (Quanjer et al. 1997). The methods for evaluating PEF variability are to compare the difference between the maximum and minimum value during the day (more than 20 % and 60 L/min) (Quanjer et al. 1997, Global Initiative for Asthma, 2012), or to compare the difference of PEF value before and after bronchodilator inhalation (at least 15 % and 60L/min) (Quanjer et al. 1997, Global Initiative for Asthma, 2012). It is recommended that the measurements should be

done over a period of two weeks (Reddel et al. 1995, Quanjer et al. 1997, Global Initiative for Asthma, 2012).

FVS is the preferred method for measuring airflow limitation and reversibility to establish an asthma diagnosis. Measurements of forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), and FEV1/FVC ratio are the most important in asthma diagnosis. An increase in FEV1 or FVC of at least 12 % and 200 ml from the pre-bronchodilator value is indicative of the presence of asthma (Bright and Burge 1996, Pellegrino et al. 2005, Global Initiative for Asthma, 2012).

Physical activity is an important cause of asthma symptoms in most asthma patients. A six- to eight-minute running protocol is easily performed in clinical practice and can establish a firm asthma diagnosis (Anderson et al. 2002). Pulmonary function measurements via the FEV1 are determined before and after exercise. The decrease of value FEV1 of at least 15 % after exercise is a characteristic of asthma (Anderson et al. 2002).

Airway hyperresponsiveness is a physiologic characteristic of asthma and its presence can be helpful in establishing the diagnosis of asthma. It can be identified and quantified by using bronchial challenge or provocation techniques, such as inhalation provocation with methacholine (Nieminen 1992) or with histamine (Sovijärvi et al. 1993).

In most epidemiological studies, the definitions of asthma include, in addition to doctor diagnosed asthma with objective criteria, also clinical or self-reported asthma which mostly includes asthma diagnosed by a doctor previously and asthmalike symptoms during the preceding 12 months.

2.5.3 Risk factors

A number of factors that influence an individual's risk of developing asthma have been identified. These can be divided into host factors and environmental factors. The most important host factors are genetic features, obesity and sex. The environmental factors include allergens, infections, tobacco smoke, air pollution, and dietary and occupational allergens and other irritants (Global Initiative for Asthma, 2012).

It is believed that multiple genes are involved in the pathogenesis of asthma. There are recent findings indicating that genetic factors of childhood-onset asthma differ from those of adult-onset asthma (Dijk et al. 2013). Variants at the 17q21 locus were associated with asthma in children who had had HRV wheezing illnesses and these were associated with expression of the two genes at this locus (Caliskan et al. 2013). While genes modulate many aspects of the natural history of asthma, such as susceptibility to atopy, altered lung development, and susceptibility to more severe disease, genetic markers have not improved the ability to predict the natural history of asthma independently (Holloway et al. 2010). Most probably, asthma is a combination of many multifactorial symptoms which are influenced by different genetic and environmental factors.

Male sex is a risk factor for asthma in childhood and adolescence. Doctor-diagnosed asthma is more common among boys until the age of 16 years, but after that, the prevalence of asthma starts to increase among girls and at the age of 23 years of age the prevalence is higher in girls (Anderson et al. 1992, Sears et al. 2003). The prevalence of asthma then remains higher in women during the remainder of the lifespan (Pallasaho et al. 2011).

The prevalence of sensitization to inhalation allergens continues to increase in adults; the risk factors for allergic sensitization are young age, a family history of allergy and living in an urban area (Warm et al. 2013). The prevalence of both allergic and non-allergic rhinitis doubles the risk of asthma (Shabaan et al. 2008, Pallasaho et al. 2011).

The role of outdoor air pollution in causing asthma remains controversial (American Thoracic Society 2000), but outbreaks of asthma exacerbations have been shown to occur in parallel with increased levels of air pollution (To et al. 2013).

Occupational sensitizers are estimated to be responsible for about 1 in 10 cases of asthma among adults of working age (Nicholson et al. 2005). Over 300 substances have been identified as being associated with occupational asthma, which is defined as asthma caused by

exposure to an agent encountered in the work environment (Malo et al. 2004). Most occupational asthma is immunologically mediated and has a latency period of months to years after the onset of exposure (Sastre et al. 2003).

2.5.4 Tobacco smoking

As discussed earlier, early-life exposure to tobacco smoke has been associated with an increased risk of developing asthma, other respiratory symptoms and lung function disorders in later life (Rylander et al. 1993, Lodrup Carlsen et al 1997, Stein et al. 1999b, Taussig et al. 2003, Lannerö et al. 2006, Piippo-Savolainen et al. 2006, Goksör et al. 2007, Hedman et al. 2011, Burke et al. 2012, Rehan et al. 2012). Similarly, tobacco smoke is also harmful in adulthood, being the major environmental cause of lung function impairment in adults. Active smoking in adolescence and adulthood has been found to increase the risk of current asthma (Strachan et al. 1996, Sears et al. 2003), and it is associated with an accelerated decline of lung function in people with asthma (O'Byrne et al. 2009).

In an adulthood study, European Community Respiratory Health Survey identified that participants, who had been exposed to prenatal tobacco smoke and whose parents smoked in the participants' childhood, reported more wheezing symptoms and symptoms typical for asthma, even after accounting for their own smoking behavior, exposure to environmental tobacco smoke, and occupational exposures (Accordini et al. 2012). They also had lower lung function (Cerveri et al. 2012, Accordini et al. 2012). However, bronchial reactivity and current adult-onset asthma were not associated with parental smoking (Accordini et al. 2012).

In an epidemiological study on the Genetics and Environment of Asthma, the incidence of asthma in adulthood was higher among current smokers compared to never smokers and former smokers, i.e. values of 9.7 %, 5.8 % and 3.0 %, respectively (Vignoud et al. 2011). On the other hand, asthma and chronic obstructive pulmonary disease (COPD) are prevalent obstructive lung diseases, both of which are characterized by airflow limitations. Although both conditions represent distinct pathogenetic entities, there can be significant clinical and physiological overlap between these two disorders leading to potential management difficulties for the clinician (Carolan and Sutherland 2013).

2.5.5 Role of overweight or obesity

Epidemiological studies have shown that overweight and obesity have increased concomitantly with the increase of asthma and allergy, and there has been claimed to be an association between obesity and asthma in industrialized countries in both childhood and adulthood (Shaheen et al. 1999, Kim and Camargo 2003, Gilliland et al. 2003, Gold et al. 2003, Ford 2005, Flaherman and Rutherford 2006, Beuther and Sutherland 2007, Matricardi et al. 2007, Jartti et al. 2009b, Visness et al. 2010, Papoutsakis et al. 2013). A recent review of obesity co-morbidities revealed that obesity preceded and was associated with the persistence and intensity of the symptoms of asthma in adolescence (Noal et al. 2011a). Excessive weight gain has been associated with respiratory symptoms, asthma diagnoses and decreased lung function but not necessarily with bronchial hyper-reactivity (Flaherman and Rutherford 2006, Noal et al. 2011b).

In a recent meta-analysis reviewing adult studies, being overweight (body mass index, BMI >25 kg/m²) carried a mean 1.5-fold risk and obesity (BMI >30 kg/m²) a 1.9-fold risk for the incidence of asthma within one year (Beuther and Sutherland 2007). The same effect was seen in young adults in a Finnish study (Kilpeläinen et al 2006). Obese asthma has been suggested as representing a distinct phenotype of adulthood asthma (Lugugo et al. 2010).

Obesity is generally found to be more consistently associated with asthma in women than men (Camargo et al. 1999, Shaheen et al. 1999, Beckett et al. 2001, Huovinen et al. 2003, Kim and Camargo 2003). However, there are also studies where gender had no influence on the

relationship between asthma and obesity (Shaheen et al. 1999, Luder et al. 2004, Ford et al. 2004).

When obese asthmatics were compared to non-obese subjects they were noted to report more frequent daytime and night-time symptoms and limitations of social activities or exercise tolerance due to their asthma (Lavoie et al. 2006, Lessard et al. 2008). It has been suggested that obesity increases the severity of asthma (Akerman et al. 2004, Mosen et al. 2008) although its influence seems mainly to make asthma more difficult to control (Lavoie et al. 2006, Saint-Pierre et al. 2006, Cazzoletti et al. 2007, Lessard et al. 2008). Potential factors which are involved in poorer control of the asthma in obese individuals are changes in lung mechanical properties, resistance to controller therapy, psychological factors, contribution of increased comorbidities and de-conditioning lifestyle (Boulet 2013). Obesity significantly affects symptoms, medication use, and quality of life, and in addition, obese individuals with asthma have a 4.6-fold increased risk of hospitalization for asthma compared with their non-obese asthmatic counterparts (Mosen et al. 2008).

Obesity seems to be a predisposing factor for the development of asthma, but the underlying mechanisms of its influence are still unclear. Various hypotheses have been generated to explain the link between obesity and asthma such as a common genetic predisposition, developmental changes, altered lung mechanics, the presence of a systemic inflammatory process, and an increased prevalence of associated comorbid conditions (Weiss and Shore 2004, Schaub and von Mutius 2005, Beuther et al. 2006, Shore 2008, Boulet 2013).

3 Aims of the Study

The aims of the study were to evaluate the adolescence and adulthood outcome in subjects who had been hospitalized for bronchiolitis in early childhood, to find the possible early-life risk factors for adulthood asthma and to assess the role of overweight and obesity to asthma prevalence.

The specific aims of the study were:

1. To describe the prevalence of asthma, allergy and respiratory symptoms among adolescents and adults who had required hospitalization for bronchiolitis in their early life compared with controls without a history of wheezing problems at that time.
2. To evaluate the risk of asthma in adolescence after hospitalization for RSV and rhinovirus bronchiolitis during infancy, using the within-study comparisons and comparisons with population controls.
3. To evaluate the association between weight status and asthma and allergy after early life wheezing compared with population controls in adolescence and adulthood.
4. To define the influence of early-life risk factors, like sensitization to inhaled allergens, eosinophilia and repeated wheezing episodes in early childhood, for later asthma.

4 Subjects and Methods

This thesis data comprises of two separately collected groups of study patients who had been hospitalized for bronchiolitis or pneumonia during infancy and of their selected and non-selected population controls.

4.1 BASELINE DATA OF STUDY GROUP 1981-1982

4.1.1 Study subjects

Between September 1st 1981 and August 31st 1982, 130 children with low respiratory infection (LRI), including 83 children who were hospitalized for bronchiolitis (Group 1981-1982) and 47 children who were hospitalized for pneumonia at the age of 1-23 months (median age 10 months) in the Department of Pediatrics at Kuopio University Hospital, Finland, were recruited into the study (Figure 1) (Korppi et al. 1986). Bronchiolitis was diagnosed by the presence of tachypnoea, expiratory wheezing or prolonged expirium during lower respiratory infection. A chest radiograph was taken from all children and pneumonia was diagnosed if an infiltration was detected radiologically. Three children from the pneumonia group were not included in the analyses after 3 years of age due to inappropriate follow-up data.




Figure 1. The flow chart of the study on cohort 1981-1982.

4.1.2 Collection of baseline data

The family history and case history of each child were obtained by interviewing the parents on admission and during the follow-up visits until the age of 20-35 months (Korppi et al., 1993), about asthma and allergy with only doctor-diagnosed disease being utilized (Kuikka et al. 1994). Wheezing episodes of the children were separately recorded for the age periods of 0-12 months and 12-24 months, and if wheezing was present at least 3 times before 24 months of age (including the index episode), it was classified as repeated (Korppi et al., 1993). The diagnosis of atopic and non-atopic dermatitis was confirmed by a dermatologist in all cases in whom there was dermatitis in the child reported by a parent (Korppi et al. 1994)

4.1.3 Laboratory tests and early-life data on allergy

Virus etiology for seven common respiratory viruses (RSV, parainfluenza viruses types 1, 2 and 3, adenovirus and influenza A and B viruses) was determined from antigen and antibody assays from nasopharyngeal aspirates (NPA) and paired serum samples which were obtained from 33 patients with bronchiolitis and from 19 subjects with pneumonia.

Total serum levels of immunoglobulin E (IgE) (ALK, Allergologiska Laboratorium, Copenhagen, Denmark) was determined and was considered as elevated if the concentration was more than +2SD above the mean for non-atopic Finnish children (≥ 60 kU/l) (Saarinen et al., 1982) at either of the two measurements at 6-11 and/or 18-23 months of age (Kuikka et al., 1994). Sensitization was studied by assaying for allergen-specific IgE (ALK, Allergologiska Laboratorium, Copenhagen, Denmark) to 8 common inhalant allergens (birch, timothy grass and mugwort pollens, spores of *Cladosporium herbarum*, cat and dog epithelial dander, and two house dust mites, *Dermatophagoides farinae* and *D. pteronyssimus*)

in serum at 18-23 months (N=67) or at 30-35 months of age (N=76). A concentration over the detection level (0.35 kU/l) on either occasion was regarded as evidence of sensitization to that allergen (Paganelli et al. 1998)

Blood eosinophils (B-Eos) counts were determined on admission during acute infection and 4-6 weeks later during convalescence using a counting chamber (Lewis et al., 1975). These determinations were done on both occasions in 79 (95%) children. The cell counts were expressed as continuous absolute values, and eosinophilia was defined by $> 0.45 \times 10^9 / l$ (Eisen 1980).

4.1.4 Previous follow-up of the cohort

Since the index episode of wheezing in the children with bronchiolitis and pneumonia, they were prospectively followed up during clinical visits at 4.5-6 years (pneumonia cases not included) (Kuikka et al. 1994), at 8.5-10 years of age (Korppi et al. 1994) and at the age of 18-21 years (Piippo-Savolainen et al. 2004). A postal questionnaire on asthma symptoms and medication was sent to study subjects at the age of 13.5-16 years (Hyvärinen et al. 2005a). In every clinical study phase, asthma and allergy status was carefully examined and screened also via a questionnaire. Asthma was defined as ≥ 3 wheezing episodes ever in life at the age of 8.5-10 years (Korppi et al. 1994) and physician diagnosed or treated asthma or wheezing symptoms within the preceding 12 months at the age of 13.5-16 (Hyvärinen et al. 2005a) and 18-21 years (Piippo-Savolainen et al. 2004).

4.2 BASELINE DATA ON STUDY GROUP 1992-1993

4.2.1 Study subjects

Between January 1st 1992 and November 2nd 1993, 100 children aged 1-23 months (median age 10 months) were recruited into the prospective follow-up study in the Department of Pediatrics at Kuopio University Hospital, Finland (Figure 2) (Reijonen et al. 1995). The inclusion criteria were the presence of wheezing and respiratory distress during acute respiratory infection. Patients were excluded if they had a history of chronic cardiorespiratory disease, including asthma, if they had been received bronchodilators within six hours, or if the acute respiratory failure was threatening.




Figure 2. The flow chart of the study on cohort 1992-1993.

4.2.2 Collection of baseline data

The family history of asthma, allergy and atopic dermatitis and baseline data in the child were obtained by interviewing the parents on admission of the children by using a structured questionnaire. The diagnoses made by physician were utilized in these analyses. The wheezing history, as well as those of maternal smoking during pregnancy and passive smoking during infancy were also recorded (Reijonen et al. 1995).

4.2.3 Laboratory tests

A venous blood sample was drawn from each patient during the index episode of wheezing and at the control visits 6 and 16 weeks later (Reijonen et al. 1997). Serum levels eosinophil cation protein (S-ECP), B-Eos and total IgE were determined. S-ECP was determined according to the instructions of the manufacturer (Pharmacia ECP RIA, Pharmacia, Uppsala, Sweden) and B-Eos were counted in an automated cell counter (Coulter Counter STKS, Coulter Electronics, Hialeah, FL). The cut-off limits for the elevated values were $> 16 \mu\text{g/l}$ for S-ECP (Peterson et al. 1991), $> 0.45 \times 10^9/\text{l}$ for B-Eos (Eisen 1980) and $\geq 60 \text{ kU/l}$ for total IgE (Saarinen et al. 1982). All the primary results have been described earlier in detail (Reijonen et al. 1997a).

In 2000, allergen specific IgE (sIgE) antibodies (Phadiatop Combi®) were determined from frozen serum samples, which had been obtained during the index episode of wheezing, by fluoroenzyme-immunometric assay, UniCAP™ (Pharmacia, Uppsala, Sweden). First, the presence of sIgE antibodies to mixtures of inhalant allergens (timothy grass, birch and mugwort pollens, cat, dog and horse epithelial danders, spores of *Cladosporium herbarum* and house dust mites, *Dermatophagoides pteronyssimus*) and food

allergens (egg white, cow's milk, fish, wheat, peanut and soya bean) was screened by the detection limit ≥ 0.35 kU/l (Paganelli et al. 1998) and if it was positive, serum sIgE antibodies were measured with same limit.

On admission, NPAs were taken by suctioning a mucus specimen from the nostrils with a disposable extractor. Direct detection of viral antigens by time-resolved fluoroimmunoassay (TR-FIA) was available for RSV, parainfluenza virus types 1, 2 and 3, influenza A and B viruses, and adenovirus (Reijonen et al. 1997). Serology by complement fixation (CF) was examined for the same respiratory viruses in paired sera taken 6 weeks apart: four-fold or greater increases in titers were defined as a positive result (Reijonen et al., 1997a).

In 2000, 81 frozen good-quality NPA samples were evaluated by reverse transcription-polymerase chain reaction (RT-PCR) assay for detection of rhinoviruses, enteroviruses and coronaviruses (strains 229E and OC-43) (Kotaniemi-Syrjänen et al. 2003b). In 2002, the RSV genome was detected by RT-PCR from NPA samples in 61 cases (Kotaniemi-Syrjänen et al. 2005).

The ECP concentration was determined from the frozen NPA samples according to the instructions of the manufacturer (Pharmacia ECP RIA, Pharmacia, Uppsala, Sweden). The ECP concentration was expressed as nanograms (ng)/g of NPA (NPA ECP) after correction for dilution 0.9% NaCl (Reijonen et al. 1997b). The receiver operating characteristic (ROC) curve analysis was applied to determine the cut-off concentration for NPA ECP which would maximize true positive cases and minimize false positive cases; the best cut-off limit for NPA ECP was 815.0 ng/g with relation to both teenage asthma and its relationship to persistent childhood asthma (Hyvärinen et al. 2010).

4.2.4 Previous follow-up of the cohort

After the index episode of wheezing, the study subjects visited the outpatient clinic at 6 and 16 weeks, 8 and 12 months and 3 years later (Reijonen et al. 2000) to monitor the respiratory status and to check for allergic manifestations in the children. At the 3-year follow-up visit, the children were between 3.2-5.1 years of age. Children having at least 3 episodes of physician-diagnosed bronchial obstruction (the index episode included) were considered as asthmatic. The clinical follow-up visits were arranged also at 5.8-8.8 years (Kotaniemi-Syrjänen et al. 2002) and 10.9-13.7 years of age (Hyvärinen et al. 2005). Symptoms suggestive of asthma and allergies were recorded and the baseline pulmonary function was examined by flow volume spirometry (FVS) (Medikro, Kuopio, Finland). The FVS was followed by the exercise challenge test (ECT), which consisted of 8-minute free running outdoors at the heart rate of $\geq 80\%$ of maximum (Kotaniemi-Syrjänen et al., 2002, Hyvärinen et al., 2007). Asthma was considered to be present if 1) the child was on continuous maintenance or intermittent anti-inflammatory medication for asthma or if 2) she/he had suffered from repeated (≥ 2) episodes of wheezing or prolonged (≥ 4 weeks) cough not related to infections during the preceding 12 months as reported by parents, and ECT was regarded as positive (Kotaniemi-Syrjänen et al., 2002, Hyvärinen et al., 2007).

4.3 CONTROL SUBJECTS

This study had two various control groups. In 1979-1980 72 newborns without a family history of atopy were recruited as controls with no intervention in a birth cohort study on atopy prevention (Pöysä et al. 1988) and there after they have been prospectively followed up (Pöysä et al. 1991, Piippo-Savolainen et al. 2004). None of these controls have required hospitalization for bronchiolitis or other lower respiratory infections before the age of two years. This group was used as a control group for the group 1981-1982 in earlier phases of the study (Piippo-Savolainen et al. 2004) and now in the first study of the present thesis.

For this study a separate control group was recruited from the Population Register Centre, Finland. These subjects in the control group were nonselected population-based controls who were born in the primary area of Kuopio University Hospital similarly to the bronchiolitis patients and they were also matched for gender and the birth month.

4.4 QUESTIONNAIRE FOLLOW-UP IN 2008

In the spring of 2008 a questionnaire was sent to the two study groups and to the controls. The questions in the questionnaire were focused on asthma, allergy, respiratory symptoms and family history of asthma and allergy.

4.4.1 Study subjects in Group 1981-1982

The questionnaire was sent to 78 study subjects and fifty-nine subjects (76%), 37 males and 22 females, from the Group 1981-1982 responded to the follow-up questionnaire in the spring 2008 at the median age of 27.3 years (range 26.3-28.6).

Fifty-one subjects with early RSV LRI hospitalization in years 1981-1982, and 40 (78%) of them, 22 males and 18 females, answered. Their median age was 27.0 years (range 26.4-28.5). The presentation of RSV LRI in infancy was classified by clinical and radiological criteria (obstruction and/or infiltration in lung). Twelve of them had infiltration in the lung but no obstruction, 14 subjects had obvious obstruction, but they did not have any infiltration evident in the thoracal x-ray and 14 of them had both obstruction and the infiltration in the lung.

Fifty-eight study subjects from the Group 1981-1982 reported their weight and height values in the questionnaire.

4.4.2 Study subjects in Group 1992-1993

The questionnaire was sent to a total of 96 Group 1992-1993 study subjects for whom a current address was available and 67 (70%), 45 males and 22 females, answered at a median age of 16.5 years (range 15.1-18.1). On average, the follow-up time from the hospitalization for wheezing in infancy was 15.6 years.

From 67 study subjects, the causative agent for bronchiolitis in infancy was RSV in 22 cases which in 16 cases RSV was the only virus, in one case there was a mixed infection with rhinovirus and in five cases there was a mixed infection with other viruses. In 19 cases the causative agent was rhinovirus. In 16 cases rhinovirus was the only virus which was found. In one case there was mixed infection with RSV and in two cases mixed infection with other viruses.

Sixty of the study subjects from the Group 1992-1993 reported their weight and height values in the questionnaire.

4.4.3 Control subjects

Thirty-nine subjects (54%) from control group in the atopy prevention study, 21 males and 18 females, responded to the questionnaire at median age of 28.5 years (range 28.2-28.7)

For the Group 1981-1982, it was possible to obtain a 4:1 ratio for the 82 cases (55 males and 27 females: one study subject had died) by accessing the nonselected population-based, gender and age matched controls from the Population Register Centre (Finland). The questionnaire was sent to 328 controls and 121 (37%) answered. From these 121 subjects, a control group of 105 subjects was constructed. This group included 60 females, two controls for each of the female cases selected according to the closest birth days (+/- 30 days) and all 61 males who answered to the questionnaire, on average 1.65 controls for each the male case.

For 51 subjects with RSV LRI hospitalization in 1981-1982, it was also possible to obtain population-based controls in a 4:1 ratio. The questionnaire was sent to 204 controls and 99 answered. From this group a control group of 80 subjects was selected, two controls for

each of the 40 cases who answered to the questionnaire. The controls chosen were matched for gender and birth month.

A population-based control group was also obtained for the Group 1992-1993. For the 99 cases (71 males and 28 females; one subject had earlier declined to participate in future follow-ups) the questionnaire was sent to 396 controls of whom 155 (39%) answered to and all of them, 104 males and 51 females, were included in the control group.

4.4.4 Posted questionnaire

The questionnaire comprised questions on the presence of wheezing symptoms, over four weeks of persistent cough not related to an infection, repeated night cough and doctor-diagnosed asthma. In the case of doctor-diagnosed asthma, the time of the asthma diagnosis was recorded as follows: during the preceding 12 months, during the preceding 24 months or ever in life. The use of maintenance medication (inhaled corticosteroids or leukotriene antagonists) and that of on-demand bronchodilator medication for asthma were recorded but only for the preceding 12 months.

The presence of nasal or eye symptoms (runny or stuffy nose, itchy or bloodshot eyes not related to infection) was inquired as was the presence of skin symptoms which could be suggestive of atopic dermatitis.

Doctor-diagnosed asthma was recorded separately for the mother, father and siblings and the children of the subjects.

The participants were asked to estimate how many cigarettes they smoked daily. The daily consumption of one or more cigarettes during the preceding 12 months was defined as current smoking.

In addition, the weights and heights were inquired in orders to permit calculation of body mass index (BMI).

4.4.5 Definition of asthma

Bronchial asthma was defined by two different ways reflecting the degree of certainty of the diagnosis. (1) Current doctor-diagnosed asthma: either the asthma had been diagnosed by a doctor during the preceding 24 months, or the subject had been using maintenance medication for asthma during the preceding 12 months. (2) Current self-reported asthma: either the subject used weekly on-demand bronchodilating drugs or asthma had been diagnosed by a doctor previously and the subject had experienced the presence of wheezing symptoms, prolonged cough or repeated night cough during the preceding 12 months. Current doctor-diagnosed asthma was an inclusion criterion with both definitions.

4.4.6 Definition of allergy

The months when the subject had suffered symptoms like runny or stuffy nose, itching or bloodshot eyes were recorded for the preceding 12 months. The calendar year was divided into four periods (spring from March to May, summer from June to August, autumn from September to November and winter from December to February). Allergic rhinitis and allergic conjunctivitis were defined to be present if nasal and/or eye symptoms, respectively, occurred during the spring or summer time (hay fever).

There was evidence of atopic dermatitis if the study subject reported itchy eczema in typical areas.

4.4.7 Definition of overweight and obesity

Body mass index (BMI) was calculated by using the equation: weight (kg) / height (m)². Overweight was defined as BMI > 25 kg/m² and obesity as BMI > 30 kg/m². Age- and sex-specific BMI standard deviation score (BMI-SDS), also called the Z-score, was assessed for all less than 18 years of age study subjects and controls using the recently published population-based Finnish growth references (Saari et al. 2011). BMI-SDS > 1.16 in females

and 0.78 in males corresponds to BMI > 25 kg/m² in adolescents and refers to overweight and BMI-SDS > 2.10 in females and > 1.70 in males corresponds to BMI > 30 kg/m² in adolescents and represents obesity (Saari et al. 2011).

4.5 STATISTICAL ANALYSES

The data were analyzed using SPSS 14.0-19.0 software (SPSS Inc., Chicago, IL, USA). In the univariate analyses, Pearson's Chi square test and Fisher's exact test were used for dichotomous data. Fisher's exact test was used when the expected frequency for any cell was < 5. The result was considered as statistically significant if the p value was < 0.05. The risks are expressed as odds ratios (OR) and their 95% confidence intervals (95% CI).

The logistic regression was used in the multivariate analyses to calculate the adjusted ORs (aOR) and related 95% CIs.

4.6 ETHICS

The study was approved by the Research Ethics Committee of Kuopio University and Kuopio University Hospital. Informed written consent was obtained from the study subjects and if needed from at least one of the parents.

5 Results

5.1 OUTCOMES IN ADULTHOOD AFTER WHEEZING IN INFANCY (GROUP 1981-1982)

5.1.1 Prevalence of asthma and wheezing symptoms (I, II)

The family history of asthma in parents and in siblings is shown in Figure 3.




Figure 3. A family history of asthma (%) in Group 1981-1982, in selected control group (Control group 1) and in nonselected population based controls (Control group 2). There was a statistically significant difference between Group 1981-1982 and both control groups (controls from nonatopic families followed-up from birth, Control group 1; and nonselected population based controls, Control group 2) for asthma in siblings (OR 5.68, 95% CI 1.55-20.86, and aOR 2.84, 95% CI 1.30-6.18), but not for asthma in the parents.

Twenty-eight (48%) of the Group 1981-1982 members suffered from wheezing, prolonged cough or night cough, but compared with Control group 1 and Control group 2, the difference was statistically significant only for wheezing (Table 2). As many as 41% of subjects in Group 1981-1982 smoked, compared with 17% in Control group 2 (OR 3.3, 95% CI 1.5-6.0). There were no significant differences in the incidences of allergic rhinitis or atopic dermatitis between Group 1981-1982 and either of the two control groups.

Table 2. Questionnaire data in Group 1981-1982, in selected control group (Control group 1) and in nonselected population based controls (Control group 2)

Questionnaire data	Group 1981-1982 (N=59)	Control group 1 (N=39)	OR (95% CI)	Control group 2 (N=105)	OR (95% CI)*
Wheezing symptoms	25 (42%)	11 (28%)	1.87 (0.8-4.5)	22 (21%)	2.93 (1.4-6.0)
Prolonged cough (smokers/non-smokers)	5/1 (8.5/1.7%)	3/2 (7.7/5.1%)	0.77 (0.2-2.7)	3/3 (2.8/2.8%)	1.66 (0.5-5.6)
Night cough	5 (8.5%)	7 (18%)	0.42 (0.1-1.5)	6 (5.7%)	1.44 (0.4-5.0)

*adjusted for sex and age

Current doctor-diagnosed asthma was present in 20% of the Group 1981-1982 subjects, compared with 5% in the two control groups. The risk of doctor-diagnosed asthma in Group 1981-1982 was 2.8-fold when compared with Control group 1 and 5.0 fold when compared with Control group 2.

Self-reported asthma was present in 41% of the Group 1981-1982 subjects. The figures in control groups 1 and 2 were 10% and 7%, respectively. The risk of self-reported asthma in Group 1981-1982 was 13.5-fold (95% CI 2.90-63.0) *vs.* Control group 1, and 11.0 fold (95% CI 4.19-29.1) *vs.* Control group 2, respectively. The results were robust and remained significant even after to adjustments for age, gender, current smoking and allergic rhinitis.




Figure 4. Asthma by two definitions in Group 1981-1982, in selected control group (Control group 1) and in nonselected population based controls (Control group 2). p* Group 1981-1982 *vs.* Control group 1 / Control group 2

When a subgroup of 24 young adult with self-reported asthma (doctor-diagnosed asthma included) were compared with the two control groups, there were significant differences in the presence of current wheezing symptoms, current allergic rhinitis and previous asthma, as well as with the presence of asthma in siblings and in current smoking (Table 3). When an identical comparison was performed for the subgroup of 12 subjects with current doctor-diagnosed asthma, the differences were significant only for current wheezing symptoms, previous asthma and asthma in siblings (data not shown).

Table 3. Questionnaire data in 24 young adults with current self-reported asthma (doctor-diagnosed included) from Group 1981-1982, compared with Control group 1 and with Control group 2

Questionnaire data	Current self-reported asthma (N=24)	OR (95% CI) vs. Control group 1	OR (95% CI)* vs. Control group 2
Asthma in siblings	13 (54%)	13.79 (3.3-57)	7.47 (2.8-20)
Current smoking	11 (46%)	2.15 (0.7-6.2)	4.00 (1.5-11)
Wheezing symptoms	22 (92%)	28.00 (5.6-140)	42.20 (9.2-190)
Allergic rhinitis	16 (67%)	3.43 (1.2-10)	2.66 (1.0-6.8)

*adjusted for sex and age

In the LRI group, there were 22 (55%) men and 18 women who had RSV infection. This group (N=40) was compared with age and gender matched population-based controls (N=80), overweight (aOR 3.3; 95% CI 1.5-7.3), smoking (aOR 2.7; 95% CI 1.1-6.3), wheezing symptoms (aOR 2.8; 95% CI 1.15-6.75), and self-reported asthma (aOR 11.4; 95% CI 3.0-44) were more common in cases than in controls.

5.1.2 Early predictive factors for adulthood asthma (I)

Early-life risk factors, including parental asthma, and atopic dermatitis, non-RSV bronchiolitis, eosinophilia $> 0.45 \times 10^9/l$, total IgE > 60 IU/l, presence of allergen-specific IgE, and repeated wheezing, assessed at < 24 months of age, were analyzed within Group 1981-1982. None of the early-life factors were significant as risk factors for doctor-diagnosed or self-reported asthma in adulthood.

5.1.3 Comparison between RSV and non-RSV bronchiolitis

There were 22 (55%) men and 18 women who had suffered a RSV infection including both bronchiolitis and pneumonia cases. When they were compared with age and gender matched population-based controls, overweight (aOR 3.3; 95% CI 1.5-7.3), smoking (aOR 2.7; 95% CI 1.1-6.3), wheezing symptoms (aOR 2.8; 95% CI 1.2-6.8), and self-reported asthma (aOR 11.4; 95% CI 3.0-44) were more common in the cases than in the controls. The analyses were adjusted for age and gender.

5.1.4 Overweight or obesity (III)

The mean BMI of the Group 1981-1982 was 25.95 kg/m² at median age of 27.3 years; 54.4% were overweight and 13.6% were obese. The corresponding figures had been 24.17 kg/m², 37.2% and 11.1% at median age of 19.0 years. There were no significant differences in BMIs between the Group 1981-1982 and Control group 2 at median age of 27.3 years, or between the measurements at median age of 27.3 and 19.0 years.

There were no significant differences between the overweight and normal weight subjects in Group 1981-1982 in the extent of respiratory symptoms or allergic manifestations at 26-29 years of age or at 18-20 years of age. The result remained negative at both ages also when obese subjects were compared with normal weight subjects (data not shown). Overweight displayed no significant association with doctor-diagnosed asthma, self-reported asthma or the use of inhaled corticosteroids at the median age of 27.3 years. As expected, asthma by all definitions was more common in Group 1981-1982 than in Control group 2. However, in overweight subjects, the difference between the cases and controls was significant only for self-reported asthma (Figure 5).




Figure 5. Outcome in Group 1981-1982 at 26-29 years of age in relation to weight status. p^* = Normal weights in Group 1981-1982 vs Control group 2, $p\#$ = Overweights in Group 1981-1982 vs Control group 2

Overweight had no significant association with doctor-diagnosed asthma, self-reported asthma or use of inhaled corticosteroids at median age of 19.0 years (data not shown). Being overweight at 18-20 years of age did not predict asthma at 26-29 years of age.

5.2 OUTCOME IN ADOLESCENCE AFTER WHEEZING IN INFANCY (GROUP 1992-1993)

5.2.1 Prevalence of asthma and wheezing symptoms (IV)

There were more parents with asthma (aOR 2.6; 95% CI 1.3-5.0), siblings with asthma (aOR 2.1; 95% CI 1.0-4.3) and current wheezing symptoms (aOR 3.4; 95% CI 1.7-6.8) in Group 1992-1993 as compared with the population-based controls in an analysis adjusted for sex and age. There were no statistical differences in cough symptoms, allergic rhinitis or atopic dermatitis between Group 1992-1993 subjects and controls.

Thirty (30%) of Group 1992-1993 subjects had current doctor-diagnosed asthma and 64% had self-reported asthma. The respective figures in the control group were 5% and 11%, and these differences were statistically significant in multivariate analysis (Table 4). In the multivariate model adjusted for sex, age, smoking, allergic rhinitis asthma in parents and asthma in siblings, bronchiolitis in infancy remained as an independent risk factor for asthma at 15-18 years of age.

Table 4. Asthma as evidenced by two definitions in Group 1992-1993 and in population-based control group

Definition of asthma	Group 1992-1993 (N=67)	Control group (N=155)
Current doctor-diagnosed asthma	20 (30%)	8 (5.2%)
OR (95% CI)*	7.94 (3.3-19.3)	1.00
OR (95% CI)#	10.65 (3.8-29.7)	1.00
Current self-reported asthma	43 (64%)	17 (11%)
OR (95% CI)*	14.69 (7.2-30.0)	1.00
OR (95% CI)#	20.08 (8.9-45.4)	1.00

* adjusted for sex and age, # adjusted for sex, age, smoking, allergic rhinitis, asthma in parents, asthma in siblings.

Asthma in parents was associated with both current doctor-diagnosed asthma (aOR 3.8; 95% CI 1.4-10.2) and self-reported asthma (aOR 2.8; 95% CI 1.3-5.8) compared with control group in analysis adjusted for sex and age. Wheezing symptoms during the preceding 12 months were associated with current asthma by both definitions; doctor-diagnosed asthma (aOR 13.7; 95% CI 4.7-39.6) and self-reported asthma (aOR 5.9; 95% CI 2.8-12.8). Allergic rhinitis was associated only with doctor-diagnosed asthma (aOR 2.7; 95% CI 1.1-7.0).

5.2.2 Early predictive factors for adolescence asthma (IV)

The presence of atopic dermatitis in infancy (aOR 5.2; 95% CI 1.1-25.5) and elevated blood eosinophils $> 0.45 \times 10^9/l$ on admission (aOR 10.4; 95% CI 1.2-90.6) were significant predictors of self-reported asthma. The results were also similar and significant if only cases of doctor-diagnosed asthma were included. The presence of at least one allergen-specific IgE > 0.35 kU/l predicted doctor-diagnosed asthma (aOR 6.0; 95% CI 1.1-33.0) but not self-reported asthma. Maternal smoking during pregnancy, passive smoking during infancy,

pre-bronchiolitis wheezing, serum ECP > 16 µg/l, NPA ECP > 815 ng/g were not significant risk factors for the presence of doctor-diagnosed or self-reported asthma in adolescence.

When viral etiology of bronchiolitis in infancy (RSV, mixed included; RV, mixed included; non-RSV non-RV), asthma in parents, atopic dermatitis in infancy, eosinophilia in infancy, and positive allergen-specific IgE at < 24 months of age were included in the same logistic regression model, only atopic dermatitis remained as an independently statistically significant early life predictor of doctor-diagnosed asthma in adolescence in Group 1992-1993 (OR 4.4; 95% CI 1.1-18.4), and none of the factors was an independent predictor of self-reported asthma in adolescence (data not shown).

5.2.3 Comparison between RSV and non-RSV bronchiolitis (IV)

Current doctor-diagnosed asthma was presented in 23.8-25.0% of Group 1992-1993 subjects with RSV bronchiolitis and in 25.0-27.8% of Group 1992-1993 with HRV bronchiolitis, depending on whether mixed infection with other viruses was included or excluded. The respective values for self-reported asthma were 47.6-50.0% (RSV) and 81.3-83.3% (HRV) (Table 5). Current self-reported asthma was more common in non-RSV than in RSV patients and more common in HRV than RSV patients in Group 1992-1993 (83.3% vs 47.6%, $p=0.023$, mixed infections included; 81.3% vs 50.0%, $p=0.067$, mixed infections excluded).

RSV and HRV bronchiolitis in infancy increased the asthma risk at 15-18 years of age according to both univariate and multivariate analyses. In the multivariate analyses the statistical significance of the differences between the groups was assessed with logistic regression analysis, adjusted first for age and gender and further also for current smoking, allergic rhinitis, asthma in parents, and asthma in siblings.

Table 5. Viral etiology of hospital-treated bronchiolitis in infancy as a risk factor for asthma in adolescence

Viral etiology of bronchiolitis	Current doctor-diagnosed asthma OR (95%CI)[#]	Current self-reported asthma OR (95% CI)[#]
RSV, mixed infections included (N=21)	5 (24%) 5.7 (1.6-20.2)	10 (48%) 7.2 (2.6-19.8)
RSV, mixed infections excluded (N=16)	4 (25%) 6.5 (1.6-26.2)	8 (50%) 7.6 (2.5-23.1)
Non-RSV (N=45)	15 (33%) 9.1 (3.5-23.7)	33 (73%) 23.5 (10.0-55.2)
HRV, mixed infection included (N=18)	5 (28%) 7.3 (2.1-26.0)	15 (83%) 46.7 (11.6-188)
HRV, mixed infection excluded (N=16)	4 (25%) 6.3 (1.6-24.8)	13 (81%) 41.1 (10.0-169)
Non-HRV (N=34)	11 (32%) 8.8 (3.2-24.4)	21 (62%) 13.8 (5.7-33.0)

[#]logistic regression, adjusted for age and sex

5.2.4 Overweight or obesity (V)

Weight and height data were available from 60 participants in Group 1992-1993 subjects and from 152 population controls. Only three (5.0%) were obese in Group 1992-1993, and 11 (18.3%) were overweight. There were no significant differences between the groups in BMI-SDS or in the presence of overweight or obesity. There were only four subjects (two in both groups, all males) who were underweight.

In Group 1992-1993, only two (14.3%) of the overweight subjects reported current wheezing symptoms versus 20 (43.5%) of the normal weight subjects ($p=0.047$). There were no other significant differences in respiratory or allergic symptoms or manifestations between the overweight and normal weight in Group 1992-1993. One of the three obese subjects in Group 1992-1993 reported previous asthma, but no-one had current wheezing symptoms or allergic rhinitis or conjunctivitis.

Current doctor-diagnosed asthma, current self-reported asthma and use of inhaled corticosteroids were more common in normal weight subjects in Group 1992-1993 than in population controls (Figure 6). The values were rather similar in normal weight and in overweight subjects in Group 1992-1993 (Figure 6).




Figure 6. Outcome in Group 1992-1993 at 15-18 years of age in relation to weight status. p* = statistical significance between normal weight in Group 1992-1993 and control group, p# = statistical significance between overweight in Group 1992-1993 and control group.

In the Group 1992-1993 subjects, there were no significant associations between overweight or obesity and doctor-diagnosed asthma, self-reported asthma, use of asthma medication or the presence of allergic rhinitis or conjunctivitis in control group (data not shown).

Weight and height data were available from the control visit at 12-13 years of age for 54 of 60 subjects in the Group 1992-1993. Being overweight or obese at that age did not predict current asthma by either definition nor did it predict allergic rhinoconjunctivitis (data not shown).

6 Discussion

6.1 DESIGN OF THE STUDY

This postal questionnaire study was a prospective follow-up including two separately collected study groups of patients (Group 1981-1982 and Group 1992-1993) who had been hospitalized for either bronchiolitis or pneumonia in their infancy (Korppi 1986) and population based controls. The field phase of the study was carried out in 2008.

The bronchiolitis groups were primary constructed during two different decades - 1981-1982 and 1992-1993. The study subjects were hospitalized at the age of 0-23 months, and data on early-life risk factors were carefully collected by interviewing the parents when the child was being admitted to hospital by using a structured questionnaire (shown in the appendices)(Korppi et al. 1986, Korppi et al. 1993, Korppi et al. 1994, Kuikka et al. 1994, Reijonen et al. 1995, Reijonen et al. 1996), by identifying the causative viruses via antibody and antigen assays (Korppi et al. 1986, Reijonen et al. 1998), supplemented by PCR (Group 1992-1993) (Kotaniemi-Syrjänen et al. 2003b, Kotaniemi-Syrjänen et al. 2005), by determining blood eosinophil numbers (Kuikka et al. 1994, Reijonen et al. 1997) and markers of atopy (Kuikka et al. 1994, Reijonen et al. 1997a). Both bronchiolitis groups were followed-up during regular visits to the clinic (Kuikka et al. 1994, Korppi et al. 1994, Piippo-Savolainen et al. 2004, Reijonen et al. 2000, Kotaniemi-Syrjänen et al. 2002, Hyvärinen et al. 2005).

The original study designs did not include healthy control children, instead pneumonia patients formed a non-wheezing control group for Group 1981-1982 throughout childhood. In adulthood studies, the subjects from a prospective atopy prevention study, started at birth in 1979-1980, formed a suitable control group for Group 1981-1982 (Pöysä et al. 1988). For this present study, nonselected population-based controls were obtained from the Population Register Centre for Group 1981-1982 and Group 1992-1993. The cases and controls were of similar age and gender; they came from the same population and lived in the same geographical area. Thus, for Group 1981-1982 there were two different control groups. The questionnaire was sent to study subjects for whom a current address was available. Some of them have not provided permission for the authorities to give their addresses to outsiders and three study subjects had died. The questionnaire had minor modifications, and basically was the same as that used in previous phases of this post-bronchiolitis follow-up study, as also were the definitions of doctor-diagnosed and self-reported asthma (Kuikka et al. 1994, Hyvärinen et al. 2005a).

6.2 PREVALENCE OF ASTHMA AND WHEEZING SYMPTOMS

In this present study, bronchial asthma was defined in two different ways reflecting the degree of certainty of the diagnosis, i.e. current doctor-diagnosed asthma and current self-reported asthma. The definition of self-reported asthma was based, with minor modifications, on earlier follow-up studies and with asthma definition studies (Pekkanen et al. 2005, Vianna et al. 2007).

In Group 1981-1982, the increased risk for bronchial asthma after suffering bronchiolitis at an age less than 24 months of age continued until 27 years of age, when compared with either the selected controls from non-atopic families with no early-life wheezing followed from infancy, or with the non-selected population-based controls enrolled into the present study. Depending on the definition of asthma, the prevalence of asthma was 20 – 41 % in

Group 1981-1982. The respective figures were 5 - 10 % in selected controls not at risk of asthma and allergy, and 5 - 7 % in nonselected controls. According to population-based studies the prevalence of asthma in Finnish adults is between 4 to 5% (Huurre et al. 2004, Pallasaho et al. 2011). Thus, both the selected and non-selected controls of the present study reflected well the situation in the age-specific population. In the same experimental cohort, eight years earlier the prevalence of asthma had been 30 – 41 % (Piippo-Savolainen et al. 2004), and thus, the prevalence values have remained rather constant. Further, the results are rather similar to the findings of a Canadian study (Larouche et al. 2000), where asthma was diagnosed clinically at the age of 17 – 35 years, with information about early-life wheezing of the study subjects being collected retrospectively from the patient records of two hospitals. The prevalence of asthma was 38 % after prior hospitalization for bronchiolitis before the age of 18 months, and this was significantly higher than in controls with no such history. In contrast, wheezing in infancy was not associated with asthma in adulthood in a birth cohort study from the United Kingdom (Rhodes et al. 2001, Rhodes et al. 2002). In that cohort, data on wheezing had been gathered prospectively, but the number of infants with wheezing was too small to permit any proper risk estimation. In the Tucson birth cohort study, the prevalence of asthma was 30 % at 22 years of age (Stern et al. 2008), which is in accordance with the values in the present study. In Group 1981-1982, there were more smokers than in control groups. There were no differences between smoking habits of the parents, so we can-not explain this difference between these groups.

In Group 1992-1993, there were more wheezing symptoms than in population-based controls, at the median age of 16.5 years. Doctor-diagnosed asthma was present in 30 % and self-reported asthma in 64 % of the former bronchiolitis patients. Four years earlier the prevalence of doctor-diagnosed asthma was 40 % in the same cohort, when about 30 % reported asthma, in line with the present study, and in about a further 10 %, the diagnosis was determined at the study visit (Hyvärinen et al. 2005b). In the control group, the doctor-diagnosed prevalence of asthma was 5.2 %. Ten years ago, the prevalence of asthma was 3 % in the 16-year-old, non-selected Finnish population (Huurre et al. 2004) which is rather close to the asthma prevalence in the controls in the present study. Recently, the prevalence of doctor diagnosed asthma in the Swedish population was 9.5 % stayed to be about in the age group 16 to 20 years (Wennergren et al. 2010). In a post-bronchiolitis study from Gothenburg, Sweden, 30 % of the bronchiolitis patients were suffering from asthma at ten years of age (Wennergren et al. 1997) and more, 43 %, at 17 - 20 years of age (Goksör et al. 2006). Changes in the prevalence of asthma in four post-bronchiolitis follow-up studies continued until teenage or adulthood could be seen in Figure 7. In the Tucson birth cohort study the asthma values after parent-reported early childhood wheezing treated at home were, as expected, somewhat lower, 30 % at 13 years (Stein et al. 1999) and 20 % at 16 years of age (Morgan et al. 2005).




Figure 7. Prevalence of asthma after hospitalization for bronchiolitis in early life; results from four cohorts prospectively followed up until teenage or adulthood.

6.3 OUTCOME IN RELATION TO VIRAL ETIOLOGY OF BROCHOLIOTIS AND EARLY-LIFE RISK FACTOR

The current knowledge about the long-term prognosis of an early RSV infection has emerged from bronchiolitis studies. In a systematic review, hospitalization for RSV bronchiolitis was associated with wheezing until the age of six years but not subsequently (Kneyber et al. 2000). In the most recent meta-analysis, 9 of the 15 included studies reported a significant increase in asthma prevalence after RSV hospitalization before the age of 3 years (Régnier and Huels 2013). The ages at follow-up have varied from one to 12 years, and the association weakened by age, consistently with the follow-up studies until early adolescence (Sigurs et al. 2005, Hyvärinen et al. 2005a). In young adults, the prevalence of asthma again increases (Piippo-Savolainen et al. 2004, Goksör et al. 2006, Sigurs et al. 2010). In the Swedish RSV bronchiolitis study, which included patients hospitalized at 0-11 months of age, 28 % had asthma at 13 years of age (Sigurs et al. 2005) and 33 - 39 %, depending on the definition of asthma, at 18 years of age (Sigurs et al. 2010). In Norway the prevalence of asthma was 34 % in former bronchiolitis patients at 10-16 years of age (Hovland et al. 2013). In a recent Finnish post-bronchiolitis follow-up study, the strongest independent risk factor for recurrent wheezing was rhinovirus detection followed by sensitization age less than one year and eczema in the age 7 years (Lukkarinen et al. 2013).

In the present 1981-1982 cohort, hospitalization for RSV LRI in infancy increased the risk of asthma by more than 10-fold, when compared with controls not at risk, at the median age of 27 years, independently from confounding factors such as allergy, smoking and being overweight. The risk of asthma was highest, 36 %, after pneumonia with wheezing and the risk of wheezing was highest, 50 %, after pneumonia without wheezing. The prevalence of doctor-diagnosed asthma was 13 %, and the prevalence of self-reported-asthma was 30 % in former RSV LRI patients, much higher than the values of 1.3 % and 3.8 % in the matched population-based controls. Self-reported asthma was assessed by nearly the same criteria at the median age of 9 years, and that time point, the prevalence was 22 % (Korppi et al. 2004). This slight increase observed in the prevalence of asthma in young

adulthood is in line with recent post-bronchiolitis follow-ups from the Scandinavian countries (Goksör et al. 2006, Piippo-Savolainen et al. 2004). Instead, it was not possible to confirm the link between non-RSV bronchiolitis in infancy and later asthma, though this has been observed in the earlier phases of this cohort (Piippo-Savolainen et al. 2004, Piippo-Savolainen et al. 2007b), as well as in the other bronchiolitis cohort earlier (Kotaniemi-Syrjänen et al. 2004, Hyvärinen et al. 2005b). During long-term follow-ups which start in infancy, the study subjects are faced with numerous later risk factors and disease modifying factors which weaken the effect of the early-life risk factors. Another explanation may be that ultimately only 12 – 14 subjects, depending the definition on asthma, suffered from adulthood asthma, and these numbers are too small to permit multivariate analyses which would separate the effects of early-life and later risk factors.

The risk of asthma was about 10-fold in the former rhinovirus versus former RSV bronchiolitis patients at the median age of 7.2 years in the 1992-1993 bronchiolitis cohort (Kotaniemi-Syrjänen et al. 2003). At the median age 12.3 years, the asthma risk in the former non-RSV versus former RSV bronchiolitis patients had declined to 2.5-fold and in the former rhinovirus versus non-rhinovirus bronchiolitis patients to 1.4-fold (Hyvärinen et al. 2005b). In the present 1992-1993 cohort, both RSV bronchiolitis and rhinovirus bronchiolitis in infancy were significant risk factors for both doctor-diagnosed asthma and self-reported asthma at 16.5 years of age compared with population-based controls. The lowest asthma risk, under 50 %, was found after RSV bronchiolitis and the highest, over 80 %, after rhinovirus bronchiolitis. In addition to viruses, these values emphasize the importance of the age of the subjects in bronchiolitis studies; RSV positives are usually under six months of age and rhinovirus positives over 9 months old with different outcomes (Kotaniemi-Syrjänen et al. 2003, Jartti and Korppi 2011, Koponen et al. 2012). Though RSV was the most commonly identified virus in the 0 – 23 months old infants with bronchiolitis, nearly half of the rhinovirus positive patients have been younger than six months in the most recent multicenter study from the United States (Mansbach et al. 2012).

Atopic dermatitis in infancy and positive allergen-specific IgE at less than 24 months of age are early-life features of atopy and were still predictive of asthma in adolescence in the 1992-1993 cohort. If one considers the eosinophilia markers, then it seemed that blood eosinophilia at admission did predict asthma in adolescence, but elevated serum and nasopharyngeal ECP had no predictive value for asthma. Atopy and eosinophilia often cluster in the same high-risk patients, and may even be associated with particular viruses like rhinoviruses (Jartti and Korppi 2011, Busse 2011). Atopic sensitization and viral infection may exert a synergistic effect mediated through certain receptors of innate immunity (Sly and Holt 2011). In a recent birth cohort of babies at risk for asthma and allergy, atopic sensitization preceded rhinovirus wheeze at preschool and early school-aged children, but the converse was not true, interpreted as evidence for a causal role of atopic sensitization in asthma development (Jackson et al. 2012). In the present 1992-1993 cohort, only atopic dermatitis remained as an independent predictor of current asthma in adolescence, when the factors significant in the univariate analyses were incorporated into the same multivariate model. In the present 1981-1982 cohort, none of the early-life factors were significant as predictor of asthma in adulthood.

6.4 OUTCOME IN RELATION TO OVERWEIGHT OR OBESITY

In the present study, the presence of doctor-diagnosed or self-reported asthma or the use of inhaled corticosteroids displayed no association with overweight or obesity in adolescence in Group 1992-1993 or in early adulthood in Group 1981-1982. There was also no significant association between overweight or obesity and atopic dermatitis, allergic rhinitis or allergic conjunctivitis. In the 1981-1982 bronchiolitis cohort, the results were similar at 18 – 20 years

of age. Against expectations, allergic rhinoconjunctivitis was even more common in the population-based controls.

Epidemiological studies have revealed an association between excessive weight gain and presenting or emerging asthma, at least when asthma has been assessed via the symptom history or drug consumption (Flasherman and Rutherford 2006, Beuther 2010, Noal et al. 2011). It has even been claimed that there might be a dose-response relationship between increasing asthma occurrence and increasing BMI in adults (Kilpeläinen et al. 2006, Coogan et al. 2009). In a meta-analysis, overweight (BMI > 25 kg/m²) increased the mean risk of emerging asthma by 1.5-fold and obesity (BMI > 30 kg/m²) by a mean of 1.9-fold in adults (Beuther and Sutherland 2007). In addition, asthma has improved after weight loss in adults, and this reversibility provides convincing evidence that overweight may be a significant risk factor for asthma (Eneli et al. 2008). The conflicting results obtained from epidemiological studies conducted in large population samples from those in clinical asthma studies, such as the present study, may be due to different statistical powers available for the analyses. The present results were negative also in the combined analyses of both cases and controls, which were done to check the consistency of the results after increasing the statistical power. In addition, asthma, as classified by all definitions, was even more common in normal weight subjects than in the overweight in Group 1981-1982 and in Group 1992-1993 study subjects, even though statistical significance was not reached.

In a Finnish prospective cohort study which examined both children and adults, asthma was associated with increasing BMI and prior excessive weight gain, but not earlier than at 24 - 39 years of age (Jartti et al. 2009b). In Group 1981-1982, the study subjects were only at the lower level of the observed age window, and thus the association between overweight and asthma may appear later in life. In the Finnish cohort study, no association was found between obesity-related biomarkers and asthma and allergy (Jartti et al. 2009b). There is increasing evidence from adult studies suggesting that obesity-related asthma is a distinct asthma phenotype, appearing from age of 12 - 17 years onwards (Lessard et al. 2008, Lang et al. 2011, Wenzel et al. 2013).

Most studies, independently from the design, have failed to reveal any association between overweight or obesity and allergic diseases or atopic sensitization (Jarvis et al. 2002, Ma et al. 2010), and in contrast to expectations, underweight has actually been associated with atopic sensitization (Van Gysel et al. 2009) and allergic rhinitis (Kusunoki et al. 2008) at school age. In some studies, the association between excessive weight gain and allergy has been gender-dependent, being present only in girls in their teenage years or in young women (Schachter et al. 2003, Hancox et al. 2005). In the 1992-1993 cohort of the present study, the results were negative for both females and males. In the 1981-1982 cohort, current atopy was strongly associated with asthma but not with current overweight or obesity. In a Finnish study of 18- to 25- year-old young adults, the risk of asthma increased linearly with BMI in men but not in women, and the risk of allergic rhinoconjunctivitis and atopic dermatitis increased linearly with BMI in women but not in men, perhaps indicating that different and gender-related effects body fat has on asthma and atopic disease (Kilpeläinen et al. 2006).

6.5 METHODOLOGICAL ASPECTS

6.5.1 Strengths of the study

Group 1981-1982

The main strength of the present study is the long prospective follow-up from infancy to the median age of 27 years. In fact, this present study is the longest prospective follow-up thus far published after bronchiolitis in infancy. The participation rate, 76 %, was good for a

prospective study lasting over 25 years. In infancy, the basic data were registered prospectively and carefully during their hospitalization as well as at the two control visits, including at that time advanced viral antigen determinations. The definitions of asthma were rather stringent being based on current medication, current symptoms and doctor-made asthma diagnoses either within the recent 24 months (doctor-diagnosed asthma) or earlier (self-reported asthma). Thus, the diagnosis was never based on respiratory symptoms alone since these are known to be nonspecific in obese patients (Sin et al. 2002) as well as in smokers (Kjaergaard et al. 2011). Atopic constitution and both passive and active smoking are factors significantly predisposing to both early-life wheezing and later asthma (Goksör et al. 2006, Goksör et al. 2007, Piippo-Savolainen and Korppi 2008, Piippo-Savolainen and Korppi 2009), as was seen also in the present study with the association between current allergic rhinitis and current smoking. Therefore, current smoking and current allergic rhinitis were included as covariates in the logistic regression model, and early childhood wheezing proved to be, a significant risk factor for asthma in adulthood independently from allergy and smoking.

Group 1992-1993

The main strengths of the present study are the long-term prospective follow-up time from infancy until the median age of 16.5 years and the use of matched population controls born in the same area as the former bronchiolitis patients. In addition, RSV and rhinovirus etiology of bronchiolitis had been evaluated in infancy, making it possible to conduct separate analyses for the outcomes after bronchiolitis induced by either RSV or rhinovirus. About 70% of the study subjects attended remained as participants even though the study lasted as long as 15.5 years.

6.5.2 Shortcomings of the study

Group 1981-1982

Especially, the main shortcomings of the present study are the small number of the subjects, study subjects with asthma and asthma-like symptoms at adulthood. The confidence intervals for both current doctor-diagnosed and self-reported asthma were rather large, and thus the results need to be interpreted with caution. In particular, this concerns the results of the subgroup analyses. It was not possible to conduct certain subgroup analyses, for example, to examine the severity or etiology of bronchiolitis.

The data were collected only by postal questionnaire. In addition, the in-house questionnaire was not validated, though largely used in many other phases of the study for both cohorts. The data obtained from interview and clinical studies are more reliable, but especially in clinical studies, the numbers of drop-outs are usually greater and the number of the controls must be limited.

When assessing the outcome after bronchiolitis, or after other infections in infancy, the results are highly dependent on the numbers of the controls and on how they have been selected. An important question is whether, when studying the outcome after early-life infection one should use, healthy controls, healthy population-based controls, non-selected population-based controls, controls with the same clinical presentation (but different etiologies), controls with the same etiology (but different presentations), or available population data from epidemiological surveys. The present study used two different controls, highly selected controls from nonatopic families with no infantile bronchiolitis prospectively followed-up from birth, with a 46 % attendance ratio, and nonselected, age- and gender-matched controls from the same area with no prospective follow-up data available, with a 37 % response ratio. The questionnaires were sent with the intention of obtaining by a 1:4 patient-control ratio, and in analyses, appropriate controls were included for women at 1:2 and for men at 1:1.65 patient-control ratio. Though the number of the

controls followed prospectively from birth was clearly under-powered in many of the analyses, the analyses gave surprisingly similar results with both control groups.

Unexpectedly, asthma by all definitions was even more common in normal weight individuals than in overweight subjects. Thus, the low statistical power of the study is not the main reason for the negative results concerning the association between asthma prevalence and overweight.

Group 1992-1993

The small number of the cases is also the main shortcoming of this part of the study, leading to the risk of under-powered analyses. In addition, the participation of the controls was so uneven, prohibiting conducting more powerful case-control analyses. Thus, the finding that non-RSV and rhinovirus bronchiolitis in infancy associated significantly with self-reported asthma but not with doctor-diagnosed asthma, may be due to the fact that non-RSV and rhinovirus bronchiolitis predispose only to mild asthma, or perhaps it is simply due to the under-powering of the study, i.e. there was an insufficient number of doctor-diagnosed asthma cases. The present study was a questionnaire study which carries a risk of under-estimating the number of doctor-diagnosed diseases and over-estimating the number of symptom-based diseases. The present study was an in-house questionnaire study which was not validated, though largely used in many other phases of the study for both cohorts.

The negative results of the present study i.e. the lack of any association between asthma and obesity must be interpreted with caution. Due to the small number of bronchiolitis cases and the rarity of asthma in controls, the study may have been under-powered to detect some true albeit minor differences between overweight and normal weight adolescents. The high dropout rates, 37.5 % in cases and 61 % in controls of those invited to take part in the present study, may bias the results. On the other hand, the rate of doctor-diagnosed asthma in controls (5.3 %) was virtually identical to the rate of self-reported doctor-diagnosed asthma (3 – 5 %) in the population (Huurre et al. 2004). There may be a risk of understating the body weight in questionnaire studies, but in a validation study, self-reported weight and height correlated well with measured weight and height (Hu et al. 2004). One reason for the negative results of the present study may be the highly selected study group. In these subjects, being overweight or obese may be a less important risk factor than other factors, for example, heredity, viral disease or smoke exposure in early childhood.

7 Conclusions

The aims of the present study were to evaluate the outcome in adolescence and adulthood in subjects who had been hospitalized for bronchiolitis in early childhood, and to compare that with selected controls and non-selected population controls, in an attempt to identify potential early-life risk factors for adulthood asthma and to assess the role of overweight and obesity on the prevalence of asthma.

The main conclusions that can be drawn from this present study are:

1. After hospitalization for wheezing at age less than two years, depending on the definition, 30-64 % of the subjects were suffering from asthma in adolescence and 20-41 % in adulthood. The risk was 4- to 6-fold greater than that of similar aged selected controls and non-selected population controls with not hospitalized for lower respiratory tract infection in their early lives. In the former bronchiolitis groups, there were also more wheezing symptoms. Thus, the increased asthma risk in early-life wheezers appeared to continue until at least 27 years of age.
2. In adolescence, the asthma risk seemed to be increased both if the individual had suffered bronchiolitis due to either RSV or rhinovirus in infancy. Non-RSV and rhinovirus bronchiolitis had a greater impact on the risk of self-reported asthma but not of doctor-diagnosed asthma than RSV bronchiolitis. RSV hospitalization in infancy seemed to increase, independently from several confounding factors like allergy, smoking and overweight, with the asthma risk being more than 10-fold in adulthood, but it was not a risk factor for allergic rhinitis or conjunctivitis.
3. It seems that there is no association with overweight and obesity versus asthma or allergy in adolescence and in adulthood if an individual had had to be hospitalized for bronchiolitis in infancy.
4. Atopic dermatitis in infancy was the only independently significant early life predictor of doctor-diagnosed asthma in adolescence but not any longer in adulthood after hospitalization for bronchiolitis in infancy. Instead, other early-life risk factors, like maternal smoking in pregnancy, passive smoking during infancy, blood eosinophilia in infancy, or positive allergen-specific IgE at less than 24 months of age, exerted no influence on asthma risk in adolescence and adulthood.

The present study has shown that hospitalization for bronchiolitis in infancy is a significant risk factor for asthma in adolescence and adulthood.

8 References

American Thoracic Society. What constitutes an adverse health effect of air pollution? Official statement of the American Thoracic Society. *Am J Respir Crit Care Med* 2000;161:665-673.

Accordini S, Janson C, Svanes C, Jarvis D. The role of smoking in allergy and asthma: lessons from the ECRHS. *Curr Allergy Asthma Rep* 2012;12:185-191.

Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. *Nat Rev Immunol* 2004;4:553-564.

Akerman MJH, Calacanis CM, Madsen MK. Relationship between asthma severity and obesity. *J Asthma* 2004;41:521-526.

Allander T, Jartti T, Gupta S, Niesters HGM, Lehtinen P, ¨usterback R, et al. Human bocavirus and acute wheezing in children. *Clin Inf Dis* 2007;44:904-910.

Anderson H, Pottier A, Strachan D. Asthma from birth to age 23: incidence and relation to prior and concurrent atopic disease. *Thorax* 1992;47:537-542.

Anderson SD, Beck KC, Davis MS, Dempsey JA, Derchak PA, Freed AN. Exercise-induced asthma: Pathophysiology and treatment. Champaign, III. *J Hum Kinet* 2002.

Bacharier LB, Cohen R, Schweiger T, Yin-DeClue H, Christie C, Zheng J, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. *J Allergy Clin Immunol* 2012;130:91-100.

Beckett WS, Jacobs DR, Yu X, Iribarren C, Williams OD. Asthma is associated with weight gain in females but not males, independent of physical activity. *Am J Respir Crit Care Med* 2001;164:2045-2050.

Beuther DA, Weiss ST, Sutherland ER. Obesity and asthma. *Am J Respir Crit Care Med* 2006;174:112-119.

Beuther DA, Sutherland ER. Overweight, Obesity, and Incident Asthma: A Meta-analysis of prospective epidemiologic studies. *Am J Respir Crit Care Med* 2007;175:661-666.

Bisgaard H, Szeffler S. Prevalence of asthma-like symptoms in young children. *Pediatr Pulmonol* 2007;42:723-728.

Bizzintino J, Lee W, Laing IA, Vang F, Pappas T, Zhang G, et al. Association between human rhinovirus C and severity of acute asthma in children. *Eur Respir J* 2011;37:1037-1042.

- Boulet L-. Asthma and obesity. *Clin Exp Allergy* 2013;43:8-21.
- Boyce TG, Mellen BG, Mitchel Jr EF, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. *J Pediatr* 2000;137:865-870.
- Brand HK, de Groot R, Galama JMD, Brouwer ML, Teuwen K, Hermans PWM, et al. Infection with multiple viruses is not associated with increased disease severity in children with bronchiolitis. *Pediatr Pulmonol* 2012;47:393-400.
- Brand PLP, Baraldi E, Bisgaard H, Boner AL, Castro-Rodriguez JA, Custovic A, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. *Eur Respir J* 2008;32:1096-1110.
- Braun-Fahrländer C, Riedler J, Herz U, Eder W, Waser M, Grize L, et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. *N Engl J Med* 2002;347:869-877.
- Bright P, Burge P. Occupational lung disease. 8. The diagnosis of occupational asthma from serial measurements of lung function at and away from work. *Thorax* 1996;51:857-863.
- Brussee JE, Smit HA, van Strien RT, Corver K, Kerkhof M, Wijga AH, et al. Allergen exposure in infancy and the development of sensitization, wheeze, and asthma at 4 years. *J Allergy Clin Immunol* 2005 5;115:946-952.
- Burke H, Leonardi-Bee J, Hashim A, Pine-Abata H, Chen Y, Cook DG, et al. Prenatal and passive smoke exposure and incidence of asthma and wheeze: systematic review and meta-analysis. *Pediatrics* 2012;129:735-744.
- Busse WW, Lemanske Jr RF, Gern JE. Role of viral respiratory infections in asthma and asthma exacerbations. *Lancet* 2010;376:826-834.
- Caliskan M, Bochkov Y, Kreiner-Möller E, Bönnerlykke K, Stein M, Du G, et al. Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. *N Engl J Med* 2013;368:1398-1407.
- Callaway Z, Kim C. Respiratory viruses, eosinophilia and their roles in childhood asthma. *Int Arch Allergy Immunol* 2011;155:1-11.
- Camargo CA, Weiss ST, Zhang S, Willett WC, Speizer FE. Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. *Arch Intern Med* 1999;159:2582-2588.
- Carolan B, Sutherland E. Clinical phenotypes of chronic obstructive pulmonary disease and asthma: Recent advances. *J allergy Clin Immunol* 2013;131:627-634.

Carroll KN, Gebretsadik T, Griffin MR, Dupont WD, Mitchel EF, Wu P, et al. Maternal asthma and maternal smoking are associated with increased risk of bronchiolitis during infancy. *Pediatrics* 2007;119:1104-1112.

Carroll KN, Gebretsadik T, Griffin MR, Wu P, Dupont WD, Mitchel EF, et al. Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a State Health Care Insurance Plan. *Pediatrics* 2008;122:58-64.

Carroll KN, Gebretsadik T, Minton P, Woodward K, Liu Z, Miller EK, et al. Influence of maternal asthma on the cause and severity of infant acute respiratory tract infections. *J Allergy Clin Immunol* 2012;129:1236-1242.

Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. *Am J Respir Crit Care Med* 2000;162:1403-1406.

Cazzoletti L, Marcon A, Janson C, Corsico A, Jarvis D, Pin I, et al. Asthma control in Europe: A real-world evaluation based on an international population-based study. *J Allergy Clin Immunol* 2007;120:1360-1367.

Cerveri I, Cazzoletti L, Corsico A, Marcon A, Niniano R, Grosso A, et al. The impact of cigarette smoking on asthma: a population-based international cohort study. *Int Arch Allergy Immunol* 2012;158:175-183.

Coogan PF, Palmer JR, O'Connor GT, Rosenberg L. Body mass index and asthma incidence in the Black Women's Health Study. *J Allergy Clin Immunol* 2000 ;123:89-95.

Custovic A, Simpson A. The role of inhalant allergens in allergic airways disease. *J Investig Allergol Clin Immunol* 2012;22:393-401.

Custovic A, Simpson A, Bardin PG, Le Souëf ,P. Allergy is an important factor in asthma exacerbation: A Pro/Con Debate. *Respirol* 2010;15:1021-1027.

Del Rio-Navarro BE, Blandon-Vijil V, Escalante-Domínguez AJ, Berber A, Castro-Rodriguez JA. Effect of obesity on bronchial hyperreactivity among latino children. *Pediatr Pulmonol* 2013;n/a-n/a.

Dijk FN, de Jongste JC, Postma DS, Koppelman GH. Genetics of onset of asthma. *Curr Opin Allergy Clin Immunol* 2013;13:193-202.

Eder W, Ege MJ, von ME. The asthma epidemic. *N Engl J Med* 2006;355:2226-2235.

Ege MJ, Mayer M, Normand A, Genuneit J, Cookson WOCM, Braun-Fahrländer C, et al. Exposure to environmental microorganisms and childhood asthma. *N Engl J Med* 2011 ;364:701-709.

Ehlenfield DR, Cameron K. Eosinophilia at the time of respiratory syncytial virus bronchiolitis predicts. *Pediatrics* 2000;105:79.

- Eisen AH. Eosinophilia in allergic disease of infancy, childhood and adolescence. Bierman CW and Pearlman DS, Philadelphia: Saunders W.B.; 1980;761-762.
- Eneli IU, Skybo T, Camargo CA. Weight loss and asthma: a systematic review. *Thorax* 2008;63:671-676.
- Flaherman V, Rutherford GW. A meta-analysis of the effect of high weight on asthma. *Arch Dis Child* 2006;91:334-339.
- Ford ES, Mannino DM, Redd SC, Mokdad AH, Mott JA. Body mass index and asthma incidence among USA adults. *Eur Respir J* 2004;24:740-744.
- Ford ES. The epidemiology of obesity and asthma. *J Allergy Clin Immunol* 2005 5;115:897-909.
- Frischer T, Baraldi E. Upper airway sampling. *Am J Respir Crit Care Med* 2000;162:28-30.
- Garcia-Marcos L, Martinez FD. Multitrigger versus episodic wheeze in toddlers: New phenotypes or severity markers? *J Allergy Clin Immunol* 2010;126:489-490.
- Gilliland FD, Berhane K, Islam T, McConnell R, Gauderman WJ, Gilliland SS, et al. Obesity and the risk of newly diagnosed asthma in school-age children. *Am J Epidemiol* 2003;158:406-415.
- Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2012. www.ginasthma.org.
- Goksör E, Åmark M, Alm B, Gustafsson PM, Wennergren G. The impact of pre- and post-natal smoke exposure on future asthma and bronchial hyper-responsiveness. *Acta Paediatr* 2007;96:1030-1035.
- Goksör E, Amark M, Alm B, Gustafsson PM, Wennergren G. Asthma symptoms in early childhood--what happens then? *Acta Paediatr* 2006;95:471-478.
- Goksör E, Gustafsson PM, Alm B, Amark M, Wennergren G. Reduced airway function in early adulthood among subjects with wheezing disorder before two years of age. *Pediatr Pulmonol* 2008;43:396-403.
- Gold DR, Damokosh AI, Dockery DW, Berkey CS. Body-mass index as a predictor of incident asthma in a prospective cohort of children. *Pediatr Pulmonol* 2003;36:514-521.
- Gómez R, Colás C, Sebastián A, Arribas J. Respiratory repercussions in adults with a history of infantile bronchiolitis. *Ann Allergy Asthma Immunol* 2004;93:447-451.
- Guerra S, Wright AL, Morgan WJ, Sherrill DL, Holberg CJ, Martinez FD. Persistence of asthma symptoms during adolescence: role of obesity and age at the onset of puberty. *Am J Respir Crit Care Med* 2004;170:78-85.

Hall CB. Respiratory syncytial virus and parainfluenza virus. *N Engl J Med* 2001;344:1917-1928.

Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. *N Engl J Med* 2009;360:588-598.

Halonen M, Stern D, Lohman C, Wright A, Brown M, Martinez F. Two subphenotypes of childhood asthma that differ in maternal and paternal influences on asthma risk. *Am J Respir Crit Care Med* 1999;160:564-570.

Hancox RJ, Milne BJ, Poulton R, Taylor DR, Greene JM, McLachlan CR, et al. Sex differences in the relation between body mass index and asthma and atopy in a birth cohort. *Am J Respir Crit Care Med* 2005;171:440-445.

Hedman L, Bjerg A, Sundberg S, Forsberg B, Rönmark E. Both environmental tobacco smoke and personal smoking is related to asthma and wheeze in teenagers. *Thorax* 2011;66:20-25.

Henderson J, Hilliard TN, Sherriff A, Stalker D, Shammari NA, Thomas HM. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: A longitudinal birth cohort study. *Pediatr Allergy Immunol* 2005;16:386-392.

Heymann PW, Platts-Mills TA, Johnston SL. Role of viral infections, atopy and antiviral immunity in the etiology of wheezing exacerbation among children and young adults. *Pediatr Infect Dis J* 2005;24:217-222.

Holloway JW, Arshad SH, Holgate ST. Using genetics to predict the natural history of asthma? *J Allergy Clin Immunol* 2010;126:200-209.

Hovland V, Riiser A, Mowinckel P, Carlsen K, Lødrup Carlsen KC. The significance of early recurrent wheeze for asthma outcomes in late childhood. *Eur Respir J* 2013;41:838-845.

Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE. Adiposity as compared with physical activity in predicting mortality among women. *N Engl J Med* 2004;351:2694-2703.

Huovinen E, Kaprio J, Koskenvuo M. Factors associated to lifestyle and risk of adult onset asthma. *Respir Med* 2003;97:273-280.

Huurre TM, Aro HM, Jaakkola JJK. Incidence and prevalence of asthma and allergic rhinitis: A cohort study of Finnish adolescents. *J Asthma* 2004;41:311-317.

Hyvärinen MK, Kotaniemi-Syrjänen A, Reijonen TM, Piippo-Savolainen E, Korppi M. Eosinophil activity in infants hospitalized for wheezing and risk of persistent childhood asthma. *Pediatr Allergy Immunol* 2010;21:96-103.

Hyvärinen M, Piippo-Savolainen E, Korhonen K, Korppi M. Teenage asthma after severe infantile bronchiolitis or pneumonia. *Acta Paediatr* 2005a;94:1378-1383.

Hyvärinen MK, Kotaniemi-Syrjänen A, Reijonen TM, Korhonen K, Korppi MO. Lung function and bronchial hyper-responsiveness 11 years after hospitalization for bronchiolitis. *Acta Paediatr* 2007;96:1464-1469.

Hyvärinen MK, Kotaniemi-Syrjänen A, Reijonen TM, Korhonen K, Korppi MO. Teenage asthma after severe early childhood wheezing: an 11-year prospective follow-up. *Pediatr Pulmonol* 2005b;40:316-323.

Illi S, Depner M, Genuneit J, Horak E, Loss G, Strunz-Lehner C, et al. Protection from childhood asthma and allergy in Alpine farm environments—the GABRIEL Advanced Studies. *J Allergy Clin Immunol* 2012;129:1470-1477.

Illi S, von Mutius E, Lau S, Nickel R, Grüber C, Niggemann B, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. *J Allergy Clin Immunol* 2004;113:925-931.

Illi S, von Mutius E, Lau S, Niggemann B, Grüber C, Wahn U. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. *Lancet* 2003;368:763-770.

Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. *Am J Respir Crit Care Med* 2008;178:667-672.

Jackson DJ, Lemanske Jr. RF. The role of respiratory virus infections in childhood asthma inception. *Immunol Allergy Clin North Am* 2010;30:513-522.

Jartti T, Lehtinen P, Vanto T, Hartiala J, Vuorinen T, Mäkelä M et al. Evaluation of the efficacy of prednisolone in early wheezing induced by rhinovirus or respiratory syncytial virus. *Pediatr Infect Dis J* 2006;25:482-488.

Jartti T, Lee W, Pappas T, Evans M, Lemanske RF, Gern JE. Serial viral infections in infants with recurrent respiratory illnesses. *Eur Respir J* 2008;32:314-320.

Jartti T, Lehtinen P, Vuorinen T, Ruuskanen O. Bronchiolitis: Age and previous wheezing episodes are linked to viral etiology and atopic characteristics. *Pediatr Inf Dis J* 2009a;28:311-317.

Jartti T, Saarikoski L, Jartti L, Lisinen I, Jula A, Huupponen R, et al. Obesity, adipokines and asthma. *Allergy* 2009b;64:770-777.

Jartti T, Korppi M. Rhinovirus-induced bronchiolitis and asthma development. *Pediatric Allergy Immunol* 2011;22:350-355.

Jartti T, Lehtinen P, Ruuskanen O, Vuorinen T, Österback R, van dH, et al. Respiratory picornaviruses and respiratory syncytial virus as causative agents of acute expiratory wheezing in children. *Emerg Infect Dis* 2004;10:1095-1101.

Jartti T, Lehtinen P, Vuorinen T, Koskenvuo M, Ruuskanen O. Persistence of rhinovirus and enterovirus RNA after acute respiratory illness in children. *J Med Virol* 2004;72:695-699.

Jarvis D, Chinn S, Potts J, Burney P. Association of body mass index with respiratory symptoms and atopy: results from the European Community Respiratory Health Survey. *Clin Exp Allergy* 2002;32:831-837.

Jensen ME, Collins CE, Gibson PG, Wood LG. The obesity phenotype in children with asthma. *Paediatric Respiratory Reviews* 2011;12:152-159.

Just J, Nicoloyanis N, Chauvin M, Pribil C, Grimfeld A, Duru G. Lack of eosinophilia can predict remission in wheezy infants? *Clin Exp Allergy* 2008;38:767-773.

Just J, Belfar S, Wanin S, Pribil C, Grimfeld A, Duru G. Impact of innate and environmental factors on wheezing persistence during childhood. *J Asthma* 2010;47:412-416.

Karakoc F, Remes ST, Martinez FD, Wright AL. The association between persistent eosinophilia and asthma in childhood is independent of atopic status. *Clin Exp Allergy* 2002;32:51-56.

Kilpeläinen M, Terho EO, Helenius H, Koskenvuo M. Body mass index and physical activity in relation to asthma and atopic diseases in young adults. *Respir Med* 2006;100:1518-1525.

Kim CK, Kim SW, Park CS, Kim BI, Kang H, Koh YY. Bronchoalveolar lavage cytokine profiles in acute asthma and acute bronchiolitis. *J Allergy Clin Immunol* 2003;112:64-71.

Kim S, Camargo Jr. CA. Sex-race differences in the relationship between obesity and asthma: the behavioral risk factor surveillance system, 2000. *Ann Epidemiol* 2003;13:666-673.

Kjaergaard T, Cvancarova M, Steinsvåg SK. Cigarette smoking and self-assessed upper airway health. *Eur Arch Otorhinolaryngol* 2011;268:219-226.

Kneyber M, Steyerberg E, de Groot R, Moll H. Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a quantitative review. *Acta Paediatr* 2000;89:654-60.

Koehoorn M, Karr CJ, Demers PA, Lencar C, Tamburic L, Brauer M. Descriptive epidemiological features of bronchiolitis in a population-based cohort. *Pediatrics* 2008;122:1196-1203.

Koponen P, Helminen M, Paassilta M, Luukkaala T, Korppi M. Preschool asthma after bronchiolitis in infancy. *Eur Respir J* 2012;39:76-80.

Korppi M, Halonen P, Kleemola M, Launiala K. Viral findings in children under the age of two years with expiratory difficulties. *Acta Paediatr Scand* 1986;75:457-464.

- Korppi M, Kuikka L, Reijonen T, Remes K, Juntunen-Backman K, Launiala K. Bronchial asthma and hyperreactivity after early childhood bronchiolitis or pneumonia. An 8-year follow-up study. *Arch Pediatr Adolesc Med* 1994;148:1079-1084.
- Korppi M, Piippo-Savolainen E, Korhonen K, Remes S. Respiratory morbidity 20 years after RSV infection in infancy. *Pediatr Pulmonol* 2004;38:155-160.
- Korppi M, Reijonen T, Pöysä L, Juntunen-Backman K. A 2- to 3-year outcome after bronchiolitis. *Am J Dis Child* 1993;147:628-631.
- Kotaniemi-Syrjänen A, Laatikainen A, Waris M, Reijonen TM, Vainionpää R, Korppi M. Respiratory syncytial virus infection in children hospitalized for wheezing: virus-specific studies from infancy to preschool years. *Acta Paediatr* 2005;94:159-165.
- Kotaniemi-Syrjänen A, Reijonen TM, Korhonen K, Korppi M. Wheezing requiring hospitalization in early childhood: predictive factors for asthma in a six-year follow-up. *Pediatr Allergy Immunol* 2002;13:418-425.
- Kotaniemi-Syrjänen A, Reijonen TM, Romppanen J, Korhonen K, Savolainen K, Korppi M. Allergen-specific immunoglobulin E antibodies in wheezing infants: the risk for asthma in later childhood. *Pediatrics* 2003;111:255-61.
- Kotaniemi-Syrjänen A, Vainionpää R, Reijonen TM, Waris M, Korhonen K, Korppi M. Rhinovirus-induced wheezing in infancy – the first sign of childhood asthma? *J Allergy Clin Immunol* 2003;111:66-71.
- Kudo M, Ishigatsubo Y, Aoki I. Pathology of asthma. *Front Microbiol* 2013;4:263.
- Kuikka L, Reijonen T, Remes K, Korppi M. Bronchial asthma after early childhood wheezing: a follow-up until 4.5-6 years of age. *Acta Paediatr* 1994;83:744-748.
- Kusel MMH, de Klerk NH, Kebabze T, Vohma V, Holt PG, Johnston SL, et al. Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. *J Allergy Clin Immunol* 2007;119:1105-1110.
- Kusunoki T, Morimoto T, Nishikomori R, Heike T, Ito M, Hosoi S, et al. Obesity and the prevalence of allergic diseases in schoolchildren. *Pediatr Allergy Immunol* 2008;19:527-534.
- Lang J, Hossain J, Dixon A, Shade D, Wise R, Peters S, et al. Does age impact the obese asthma phenotype?: Longitudinal asthma control, airway function, and airflow perception among mild persistent asthmatics. *Chest* 2011;140:1524-1533.
- Lannerö E, Wickman M, Pershagen G, Nordvall L. Maternal smoking during pregnancy increases the risk of recurrent wheezing during the first years of life (BAMSE). *Respir Res* 2006;7:3-6.
- Lannerö E, Wickman M, van Hage M, Bergström A, Pershagen G, Nordvall L. Exposure to environmental tobacco smoke and sensitisation in children. *Thorax* 2008;63:172-176.

Larouche V, Riverd G, Deschesnes F, Goulet R, Turcotte H, Boulet L-. Asthma and airway hyper-responsiveness in adults who required hospital admission for bronchiolitis in early childhood. *Respir Med* 2000;94:288-294.

Lavoie KL, Bacon SL, Labrecque M, Cartier A, Ditto B. Higher BMI is associated with worse asthma control and quality of life but not asthma severity. *Respir Med* 2006;100:648-657.

Lee WM, Kiesner C, Pappas T, Lee I, Grindle K, Jartti T, et al. A diverse group of previously unrecognized human rhinoviruses are common causes of respiratory illnesses in infants. *PloS One* 2007;2:e966.

Lee W, Lemanske RF, Evans MD, Vang F, Pappas T, Gangnon R, et al. Human rhinovirus species and season of infection determine illness severity. *Am J Respir Crit Care Med* 2012;186:886-891.

Lehtinen P, Ruohola A, Vanto T, Vuorinen T, Ruuskanen O, Jartti T. Prednisolone reduces recurrent wheezing after a first wheezing episode associated with rhinovirus infection or eczema. *J Allergy Clin Immunol* 2007;119:570-575.

Lemanske Jr RF, Busse WW. 6. Asthma. *J Allergy Clin Immunol* 2003;111:502-519.

Lemanske Jr. RF, Jackson DJ, Gangnon RE, Evans MD, Li Z, Shult PA, et al. Rhinovirus illnesses during infancy predict subsequent childhood wheezing. *J Allergy Clin Immunol* 2005;116:571-577.

Lemanske RF. The Childhood Origins of Asthma (COAST) study. *Pediatr Allergy Immunol* 2002;13:38-43.

Lessard A, Turcotte H, Cormier Y, Boulet L. Obesity and asthma - A specific phenotype? *Chest* 2008;134:317-323.

Lewis SM, Dacie JV editors. *Practical Haematology*. 5th ed. Edinburg: Churchill Livingstone; 1975.

Lim RH, Kobzik L. Maternal transmission of asthma risk. *Am J Reprod Immunol* 2009;61:1-10.

Lodrup Carlsen K, Jaakkola JJ, Nafstad P, Carlsen KH. In utero exposure to cigarette smoking influences lung function at birth. *Eur Respir J* 1997;10:1774-9.

Lukkarinen M, Lukkarinen H, Lehtinen P, Vuorinen T, Ruuskanen O, Jartti T. Prednisolone reduced recurrent wheezing after first rhinovirus wheeze: a 7-year follow-up. *Pediatr Allergy Immunol* 2013;24:237-243.

Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al. Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome. *J Allergy Clin Immunol* 2011;127:355-360.

Luder E, Ehrlich RI, Lou WYW, Melnik TA, Kattan M. Body mass index and the risk of asthma in adults. *Respir Med* 2004;98:29-37.

Lugogo NL, Kraft M, Dixon AE. Does obesity produce a distinct asthma phenotype? *J Appl Physiol* 2010;108:729-734.

Ma J, Xiao L, Knowles SB. Obesity, insulin resistance and the prevalence of atopy and asthma in US adults. *Allergy* 2010;65:1455-1463.

MacNeill SJ, Sozanska B, Danielewicz H, Debinska A, Kosmeda A, Boznanski A, et al. Asthma and allergies: is the farming environment (still) protective in Poland? *The GABRIEL Advanced Studies*. *Allergy* 2013;68:771-779.

Mahony JB. Detection of respiratory viruses by molecular methods. *Clin Microbiol Rev* 2008;21:716-747.

Malo JL, Lemièrè C, Gautrin D, Labrecque M. Occupational asthma. *Curr Opin Pulm Med* 2004;10:57-61.

Mamun AA, Lawlor DA, Alati R, O'Callaghan MJ, Williams GM, Najman JM. Increasing body mass index from age 5 to 14 years predicts asthma among adolescents: evidence from a birth cohort study. *Int J Obes* 2007;31:578-583.

Mannino DM, Mott J, Ferdinands JM, Camargo CA, Friedman M, Greves HM, et al. Boys with high body masses have an increased risk of developing asthma: findings from the National Longitudinal Survey of Youth (NLSY). *Int J Obes* 2006;30:6-13.

Mansbach JM, Piedra PA, Stevenson MD, Sullivan AF, Forgey TF, Clark S, et al. Prospective multicenter study of children with bronchiolitis requiring mechanical ventilation. *Pediatrics* 2012;130:e492-e500.

Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ, et al. Asthma and wheezing in the first six years of life. *N Engl J Med* 1995;332:133-138.

Martinez FD, Vercelli D. Asthma. *Lancet* 2013;382:1360-1372.

Matricardi PM, Grüber C, Wahn U, Lau S. The asthma–obesity link in childhood: open questions, complex evidence, a few answers only. *Clin Exp Allergy* 2007;37:476-484.

Matricardi PM, Illi S, Grüber C, Keil T, Nickel R, Wahn U, et al. Wheezing in childhood: incidence, longitudinal patterns and factors predicting persistence. *Eur Respir J* 2008;32:585-592.

Michel S, Busato F, Genuneit J, Pekkanen J, Dalphin J-, Riedler J, et al. Farm exposure and time trends in early childhood may influence DNA methylation in genes related to asthma and allergy. *Allergy* 2013;68:355-364.

- Midulla F, Pierangeli A, Cangiano G, Bonci E, Salvadei S, Scagnolari C, et al. Rhinovirus bronchiolitis and recurrent wheezing: 1-year follow-up. *Eur Respir J* 2012;39:396-402.
- Mikalsen IB, Halvorsen T, Eide GE, Øymar K. Severe bronchiolitis in infancy: Can asthma in adolescence be predicted? *Pediatr Pulmonol* 2013;48:538-544.
- Morgan WJ, Stern DA, Sherrill DL, Guerra S, Holberg CJ, Guilbert TW, et al. Outcome of asthma and wheezing in the first 6 years of life. *Am J Respir Crit Care Med* 2005;172:1253-1258.
- Morgan WJ, Stern DA, Sherrill DL, Guerra S, Holberg CJ, Guilbert TW, et al. Outcome of asthma and wheezing in the first 6 years of life: Follow-up through adolescence. *Am J Respir Crit Care Med* 2005;172:1253-1258.
- Mosen DM, Schatz M, Magid DJ, Camargo Jr. CA. The relationship between obesity and asthma severity and control in adults. *J Allergy Clin Immunol* 2008;122:507-511.
- Mullane D, Turner S, Cox D, Goldblatt J, Landau L, le Souëf P. Reduced infant lung function, active smoking, and wheeze in 18-year-old individuals. *JAMA Pediatrics* 2013;167:368-373.
- Nicholson PJ, Cullinan P, Taylor AJ, Burge PS, Boyle C. Evidence based guidelines for the prevention, identification, and management of occupational asthma. *Occup Environ Med* 2005;62:290-299.
- Nieminen M. Unimodal distribution of bronchial hyperresponsiveness to methacholine in asthmatic patients. *Chest* 1992;102:1537-1543.
- Noal RB, Menezes AM, Macedo SE, Dumith SC. Childhood body mass index and risk of asthma in adolescence: a systematic review. *Obes Rev* 2011;12:93-104.
- Noal RB, Menezes AM, Macedo SE, Dumith SC, Perez-Padilla R, Araújo CLP, Hallal PC. Is obesity a risk factor for wheezing among adolescents? A Prospective Study in Southern Brazil. *J Adolesc Health* 2012;51:38-45.
- O'Byrne PM, Lamm CJ, Busse WW, Tan WC, Pedersen S. The effects of inhaled budesonide on lung function in smokers and nonsmokers with mild persistent asthma. *Chest* 2009;136:1514-1520.
- Ogra PL. Respiratory syncytial virus: The virus, the disease and the immune response. *Paediatr Respir Rev* 2004;5:119-126.
- Paganelli R, Ansotegui IJ, Sastre J, Lange C-, Roovers MHW, Groot H, et al. Specific IgE antibodies in the diagnosis of atopic disease. *Allergy* 1998;53:763-768.
- Pallasaho P, Juusela M, Lindqvist A, Sovijärvi A, Lundbäck B, Rönmark E. Allergic rhinoconjunctivitis doubles the risk for incident asthma – Results from a population study in Helsinki, Finland. *Respir Med* 2011;105:1449-1456.

Papoutsakis C, Priftis KN, Drakouli M, Prifti S, Konstantaki E, Chondronikola M, et al. Childhood overweight/obesity and asthma: Is there a link? A systematic review of recent epidemiologic evidence. *J Acad Nutr Diet* 2013;113:77-105.

Pekkanen J, Sunyer J, Anto JM, Burney P, on behalf of the European Community Respiratory Health Study (ECRHS). Operational definitions of asthma in studies on its aetiology. *Eur Respir J* 2005;26:28-35.

Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. *European Respiratory Journal* 2005;26:948-968.

Peltola V, Waris M, Österback R, Susi P, Hyypiä T, Ruuskanen O. Clinical effects of rhinovirus infections. *J Clin Virol* 2008;43:411-414.

Peterson CG, Enander I, Nystrand J, Anderson AS, Nilsson L, Venge P. Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels in serum and turnover in vivo. *Clin Exp Allergy* 1991;21:561-567.

Piippo-Savolainen E, Remes S, Korppi M. Does blood eosinophilia in wheezing infants predict later asthma? A prospective 18-20-year follow-up. *Allergy Asthma Proc* 2007a;28:163-169.

Piippo-Savolainen E, Korppi M. Long-term outcomes of early childhood wheezing. *Curr Opin Allergy Clin Immunol* 2009;9:190-195.

Piippo-Savolainen E, Korppi M. Wheezy babies--wheezy adults? Review on long-term outcome until adulthood after early childhood wheezing. *Acta Paediatr* 2008;97:5-11.

Piippo-Savolainen E, Korppi M. The impact of early passive smoking on lung function in adulthood--a postbronchiolitis study. *Acta Paediatr* 2007b;96:1860-1; author reply 1861-2.

Piippo-Savolainen E, Remes S, Kannisto S, Korhonen K, Korppi M. Early predictors for adult asthma and lung function abnormalities in infants hospitalized for bronchiolitis: a prospective 18- to 20-year follow-up. *Allergy Asthma Proc* 2006;27:341-349.

Piippo-Savolainen E, Remes S, Kannisto S, Korhonen K, Korppi M. Asthma and lung function 20 years after wheezing in infancy: results from a prospective follow-up study. *Arch Pediatr Adolesc Med* 2004;158:1070-1076.

Piippo-Savolainen E, Remes S, Korppi M. Does early exposure or sensitization to inhalant allergens predict asthma in wheezing infants? A 20-year follow-up. *Allergy Asthma Proc* 2007c;28:454-461.

Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, Sporik R. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. *Lancet* 2001;357(9258):752-756.

Pöysä L, Korppi M, Remes K, Juntunen-Backman K. Atopy in childhood and diet in infancy. A nine-year follow-up study. I. Clinical manifestations. *Allergy Proc* 1991;12:107-111.

Pöysä L, Remes K, Korppi M, Launiala K. Compliance with a dietary manipulation programme in families with infants prone to atopy. *Acta Paediatr Scand* 1988;77:563-568.

Quanjer P, Lebowitz M, Gregg I, Miller M, Pedersen O. Peak expiratory flow: conclusion and recommendations of a working party of the European Respiratory Society. *Eur Respir J* 1997;24:2-8.

Rakes G, Arruda E, Ingram J, Hoover G, Zambrano J, Hayden F, et al. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. *Am J Respir Crit Care Med* 1999;159:785-790.

Reddel HK, Salome CM, Peat JK, Woolcock AJ. Which index of peak expiratory flow is most useful in the management of stable asthma? *Am J Respir Crit Care Med* 1995;151:1320-1325.

Regnier S, Huels J. Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae. *Pediatr Infect Dis J* 2013;32:820-826.

Rehan V, Liu J, Naeem E, Tian J, Sakurai R, Kwong K, et al. Perinatal nicotine exposure induces asthma in second generation offspring. *BMC Medicine* 2012;10:129.

Reijonen T, Korppi M, S., Tenhola S, Remes K. The clinical efficacy of nebulized racemic epinephrine and albuterol in acute bronchiolitis. *Arch Pediatr Adolesc Med* 1995;149:686-692.

Reijonen T, Korppi M, Kuikka L, Remes K. Anti-inflammatory therapy reduces wheezing after bronchiolitis. *Arch Pediatr Adolesc Med* 1996;150:512-517.

Reijonen TM, Korppi M. One-year follow-up of young children hospitalized for wheezing: the influence of early anti-inflammatory therapy and risk factors for subsequent wheezing and asthma. *Pediatr Pulmonol* 1998;26:113-119.

Reijonen TM, Korppi M, Kleemola M, Savolainen K, Kuikka L, Mononen I, et al. Nasopharyngeal eosinophil cationic protein in bronchiolitis: relation to viral findings and subsequent wheezing. *Pediatr Pulmonol* 1997;24:35-41.

Reijonen TM, Kotaniemi-Syrjänen A, Korhonen K, Korppi M. Predictors of asthma three years after hospital admission for wheezing in infancy. *Pediatrics* 2000;106:1406-1412.

Rhodes HL, Thomas P, Sporik R, Holgate ST, Cogswell JJ. A birth cohort study of subjects at risk of atopy . Twenty-two-year follow-up of wheeze and atopic status. *Am J Respir Crit Care Med* 2002;165:176-180.

- Rhodes HL, Sporik R, Thomas P, Holgate ST, Cogswell JJ. Early life risk factors for adult asthma: A birth cohort study of subjects at risk. *J Allergy Clin Immunol* 2001;108:720-725.
- Rylander E, Pershagen G, Eriksson M, Nordvall L. Parental smoking and other risk factors for wheezing bronchitis in children. *Eur J Epidemiol* 1993;9:517-526.
- Saari A, Sankilampi U, Hannila M, Kiviniemi V, Kesseli K, Dunkel L. New Finnish growth references for children and adolescents aged 0 to 20 years: Length/height-for-age, weight-for-length/height, and body mass index-for-age. *Ann Med* 2011;43:235-248.
- Saarinen UM, Juntunen K, Kajosaari Mea. Serum immunoglobulin E in atopic and non-atopic children aged 6 months to 5 years. A follow-up study. *Acta Paediatr Scand* 1982;71:489-494.
- Saint-Pierre P, Bourdin A, Chanez P, Daures J-, Godard P. Are overweight asthmatics more difficult to control? *Allergy* 2006;61:79-84.
- Sastre J, Vandenplas O, Park H. Pathogenesis of occupational asthma. *Eur Respir J* 2003;22:364-373.
- Schaub B, von Mutius E. Obesity and asthma, what are the links? *Curr Opin Allergy Clin Immunol* 2005;5:185-193.
- Sears MR, Greene JM, Willan AR, Wiecek EM, Taylor DR, Flannery EM, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. *N Engl J Med* 2003;349:1414-1422.
- Semple MG, Taylor-Robinson D, Lane S, Smyth RL. Household tobacco smoke and admission weight predict severe bronchiolitis in infants independent of deprivation: Prospective Cohort Study. *PLoS ONE* 2011;6:1-7.
- Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, et al. Rhinitis and onset of asthma: a longitudinal population-based study. *Lancet* 2008;372:1049-1057.
- Shaheen SO, Sterne JAC, Montgomery SM, Azima H. Birth weight, body mass index and asthma in young adults. *Thorax* 1999;54:396-402.
- Sherrill, Stein, Kurzius-Spencer, Martinez, Sherrill. On early sensitization to allergens and development of respiratory symptoms. *Clin Exp Allergy* 1999;29:905-911.
- Shore SA. Obesity and asthma: Possible mechanisms. *J Allergy Clin Immunol* 2008;12:1087-1093.
- Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B, Björkstèn B. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: A prospective cohort study with matched controls. *Pediatrics* 1995;95:500-505.

Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. *Thorax* 2010;65:1045-1052.

Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. *Am J Respir Crit Care Med* 2000;161:501-1507.

Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. *Am J Respir Crit Care Med* 2005;171:137-141.

Silverberg JI, Kleiman E, Lev-Tov H, Silverberg NB, Durkin HG, Joks R, et al. Association between obesity and atopic dermatitis in childhood: A case-control study. *J Allergy Clin Immunol* 2011;127:1180-1186.

Simpson A, Simpson B, Custovic A, Craven M, Woodcock A. Stringent environmental control in pregnancy and early life: the long-term effects on mite, cat and dog allergen. *Clin Exp Allergy* 2003;33:1289.

Sin DD, Jones RL, Man SFP. Obesity is a risk factor for dyspnea but not for airflow obstruction. *Arch Intern Med* 2002;162:1477-1481.

Singh SP, Gundavarapu S, Peña-Philippides JC, Rir-sima-ah J, Mishra NC, Wilder JA, et al. Prenatal secondhand cigarette smoke promotes Th2 polarization and impairs goblet cell differentiation and airway mucus formation. *J Immunol* 2011;187:4542-4552.

Sly P, Holt P. Role of innate immunity in the development of allergy and asthma. *Curr Opin Allergy Clin Immunol* 2011;11:127-131.

Smyth RL. Innate immunity in respiratory syncytial virus bronchiolitis. *Exp Lung Res* 2007;33:543-547.

Sonnappa S, Bastardo CM, Wade A, Saglani S, McKenzie SA, Bush A, et al. Symptom-pattern phenotype and pulmonary function in preschool wheezers. *J Allergy Clin Immunol* 2010;126:519-526.

Sovijärvi A,R., Malmberg LP, Reinikainen K, Ryttilä P, Poppius H. A rapid dosimetric method with controlled tidal breathing for histamine challenge. Repeatability and distribution of bronchial reactivity in a clinical material. *Chest* 1993;104:164-170.

Stein RT, Holberg CJ, Sherrill D, Wright AL, Morgan WJ, Taussig L, et al. Influence of parental smoking on respiratory symptoms during the first decade of life: The Tucson Children's Respiratory Study. *Am J Epidemiol* 1999;149:1030-1037.

Stern DA, Morgan WJ, Halonen M, Wright AL, Martinez FD. Wheezing and bronchial hyper-responsiveness in early childhood as predictors of newly diagnosed asthma in early adulthood: a longitudinal birth-cohort study. *Lancet* 2008;372:1058-1064.

Stern DA, Morgan WJ, Wright AL, Guerra S, Martinez FD. Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study. *Lancet* 2007;370:758-764.

Strachan DP, Butland BK, Anderson HR. Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort. *BMJ* 1996;312:1195-1199.

Strachan D. Hay fever, hygiene, and household size. *BMJ* 1989;299:1259-1260.

Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. *Pediatrics* 2006;118:1774-1793.

Taussig LM, Wright AL, Morgan WJ, Harrison HR, Ray CG, The group health medical associates. The Tucson Children's Respiratory Study: I. Design and implementation of a prospective study of acute and chronic respiratory illness in children. *Am J Epidemiol* 1989;129:1219-1231.

Thomsen S, van der Sluis S, Stensballe L, Posthuma D, Skytthe A, Kyvik K, et al. Exploring the association between severe respiratory syncytial virus infection and asthma. *Am J Respir Crit Care Med* 2009;179:1091-1097.

To T, Shen K, Atenafu EG, Guan J, McLimont S, Stocks B, et al. The air quality health index and asthma morbidity: population-based study. *Environ Health Perspect* 2013;121:46-52.

To T, Stanojevic S, Moores G, Gershon A, Bateman E, Cruz A, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. *BMC Public Health* 2012;12:204.

To T, Vydykhan TN, Dell S, Tassoudji M, Harris JK. Is obesity associated with asthma in young children? *J Pediatr* 2004;144:162-168.

Van Gysel D, Govaere E, Verhamme K, Doli E, De Baets F. Body mass index in Belgian schoolchildren and its relationship with sensitization and allergic symptoms. *Pediatr Allergy Immunol* 2009;20:246-253.

Vianna EO, Garcia CA, Bettiol H, Barbieri MA, Rona RJ. Asthma definitions, relative validity and impact on known risk factors in young Brazilians. *Allergy* 2007;62:1146-1151.

Vignolo M, Silvestri M, Parodi A, Pistorio A, Battistini E, Rossi GA, et al. Relationship between body mass index and asthma characteristics in a group of Italian children and adolescents. *J Asthma* 2005;42:185-189.

Vignoud L, Pin I, Boudier A, Pison C, Nadif R, Le Moual N, et al. Smoking and asthma: Disentangling their mutual influences using a longitudinal approach. *Respir Med* 2011;105:1805-1814.

Visness CM, London SJ, Daniels JL, Kaufman JS, Yeatts KB, Siega-Riz A, et al. Association of childhood obesity with atopic and nonatopic asthma: Results from the National Health and Nutrition Examination Survey 1999–2006. *J Asthma* 2010;47:822-829.

Visness CM, London SJ, Daniels JL, Kaufman JS, Yeatts KB, Siega-Riz A, et al. Association of obesity with IgE levels and allergy symptoms in children and adolescents: Results from the National Health and Nutrition Examination Survey 2005-2006. *J Allergy Clin Immunol* 2009;123:1163-1169.

Voets S, van Berlaer G, Hachimi-Idrissi S. Clinical predictors of the severity of bronchiolitis. *Eur J Emerg Med* 2006;13:134-138.

von Mutius E, Schwartz J, Neas LM, Dockery D, Weiss ST. Relation of body mass index to asthma and atopy in children: the National Health and Nutrition Examination Study III. *Thorax* 2001;56:835-838.

Warm K, Lindberg A, Lundback B, Ronmark E. Increase in sensitization to common airborne allergens among adults -- two population-based studies 15 years apart. *Allergy Asthma Clin Immunol* 2013;9:20.

Weiss ST, Shore S. Obesity and asthma: directions for research. *Respir Crit Care Med* 2004;169:963-968.

Wennergren G, Åmark M, Åmark K, Óskarsdóttir S, Sten G, Redfors S. Wheezing bronchitis reinvestigated at the age of 10 years. *Acta Paediatr* 1997;86:351-355.

Wennergren G, Hansson S, Engström I, Jodal U, Amark M, Brolin I, et al. Characteristics and prognosis of hospital-treated obstructive bronchitis in children aged less than two years. *Acta Paediatr* 1992;81:40-45.

Wennergren G, Ekerljung L, Alm B, Eriksson J, Lötval J, Lundbäck B. Asthma in late adolescence ? Farm childhood is protective and the prevalence increase has levelled off. *Pediatr Allergy Immunol* 2010;21:806-813.

Wenzel SE. Complex phenotypes in asthma: Current definitions. *Pulm Pharmacol Ther* 2013 Jul 20. doi:pil: S1094-5539(13)00143-0.0.1016/j.pupt.2013.07.003. [Epub ahead of print].

Wolf DG, Greenberg D, Kalkstein D, Shemer-Avni Y, Givon-Lavi N, Saleh N, et al. Comparison of human metapneumovirus, respiratory syncytial virus and influenza A virus lower respiratory tract infections in hospitalized young children. *Pediatr Infect Dis J* 2006;25:320-324.

World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: A comprehensive approach. Geneva, Switzerland: World Health Organization. 2007.

Wu P, Dupont WD, Griffin MR, Carroll KN, Mitchel EF, Gebretsadik T, et al. Evidence of a causal role of winter virus infection during infancy in early childhood asthma. *Am J Respir Crit Care Med* 2008;178:1123-1129.

Zhang H, Li Z, Diao T, Cao C, Sun H. Respiratory viruses in hospitalized children with acute lower respiratory tract infections in harbin, China. *Jpn J Infect Dis* 2009;62:458-460.

APPENDICES
KYSELYKAAVAKE
ORIGINAL PUBLICATIONS (I-V)

BRONKIOLIITIN ENNUSTE JA GENETIIKKA (BEG)

KYS, Lastenkliniikka

KYSELYKAAVAKE

Nimi: _____

Tutk.nro _____

Sosiaaliturvatunnus: _____ - _____

1. HENGENAHDISTUSOIREET

<i>Ympyröi sopiva vaihtoehto.</i>	Ei	Kyllä
Onko Sinulla ollut hengitysvaikeuksia etenkin uloshengitykseen liittyen viimeisen 12 kuukauden aikana?	0	1

Jos vastasit **Ei**, siirry kohtaan 2. Jos vastasit **Kyllä**, vastaa alla oleviin kysymyksiin.

<i>Ympyröi sopiva vaihtoehto.</i>	Ei	Kyllä
Onko hengitysvaikeuksia esiintynyt enemmän kuin kerran edeltävän 12 kk aikana?	0	1
Onko hengitysvaikeuksia esiintynyt vilustumisen yhteydessä?	0	1
Onko hengitysvaikeuksia esiintynyt liittyen siitepöly-ja/tai eläinallistukseen?	0	1
Onko hengitysvaikeuksia esiintynyt rasituksessa?	0	1
Onko hengitysvaikeuksia esiintynyt jossain muussa tilanteessa?	0	1
Kyllä-vastauksessa tilanteen kuvaus:		

2. YSKÄOIREET

<i>Ympyröi sopiva vaihtoehto.</i>	Ei	Kyllä
Onko Sinulla ollut pitkäaikaista (vähintään 4 viikkoa kestänyttä) yskää muulloin kuin hengitystieinfektion eli flunssan aikana viimeisen 12 kuukauden aikana?	0	1
Onko Sinulla esiintynyt toistuvaa yöyskää muulloin kuin hengitystieinfektion eli flunssan aikana viimeisen 12 kk aikana?	0	1

3. ASTMADIAGNOOSI

<i>Ympyröi sopiva vaihtoehto.</i>	Ei	Kyllä
Onko lääkäri todennut Sinulla astmaa viimeisen 12 kuukauden aikana? Kyllä-vastauksessa terveystieteiden keskuksen/sairaalan/palvelun tuottajan nimi ja sijainti:	0	1
Onko lääkäri todennut Sinulla astmaa viimeisen 24 kuukauden aikana? Kyllä-vastauksessa terveystieteiden keskuksen/sairaalan/palvelun tuottajan nimi ja sijainti:	0	1
Onko lääkäri todennut Sinulla koskaan astmaa? Kyllä-vastauksessa terveystieteiden keskuksen/sairaalan/palvelun tuottajan nimi ja sijainti:	0	1

4. ASTMALÄÄKITYS

<i>Ympyröikää sopiva vaihtoehto.</i>	Ei	Kyllä
Onko Sinulla ollut säännöllisessä käytössä jokin astman hoitava lääke (esim. Pulmicort, Flixotide, Beclomet , Seretide, Symbicort, Singulair) viimeisen 12 kuukauden aikana?	0	1
Onko Sinulla koskaan ollut säännöllisessä käytössä astman hoitavaa lääkettä?	0	1

<i>Ympyröi sopiva vaihtoehto.</i>	Ei	Kyllä
Onko Sinulla ollut käytössä jokin keuhkoputkia avaava lääke (esim. Bricanyl, Serevent, Ventoline, Airomir) viimeisen 12 kuukauden aikana? Kyllä-vastauksessa lääkkeen tarve, ympyröi sopivin vaihtoehto: päivittäin viikoittain kuukausittain harvemmin	0	1
Onko Sinulla koskaan ollut käytössä keuhkoputkia avaavaa lääkettä?	0	1

5. NUHAOIREET

<i>Ympyröi sopiva vaihtoehto.</i>	Ei	Kyllä
Onko Sinulla ollut aivastelua, vetistä nuhaa tai nenän tukkoisuutta muulloin kuin vilustumisen yhteydessä viimeisen 12 kuukauden aikana?	0	1

Jos vastasit **Ei**, siirry kohtaan 6. Jos vastasit **Kyllä**, vastaa alla oleviin kysymyksiin.

<i>Ympyröi sopiva vaihtoehto.</i>	Ei	Kyllä
Onko aivastelua, vetistä nuhaa tai nenän tukkoisuutta esiintynyt vuodenaikoihin liittyen? Kyllä-vastauksessa ympyröi oikeat vaihtoehdot: tammi-, helmi-, maaliskuu-, huhti-, touko-, kesä-, heinä-, elokuu-, syys-, loka-, marraskuu-, joulukuussa	0	1
Onko aivastelua, vetistä nuhaa tai nenän tukkoisuutta esiintynyt eläinkontakteihin liittyen?	0	1
Onko aivastelua, vetistä nuhaa tai nenän tukkoisuutta esiintynyt jossain muussa tilanteessa? Kyllä-vastauksessa tilanteen kuvaus:	0	1

6. SILMÄOIREET

<i>Ympyröi sopiva vaihtoehto.</i>	Ei	Kyllä
Onko Sinulla ollut silmien kutinaa, punoitusta tai vetistystä muulloin kuin vilustumisen yhteydessä viimeisen 12 kuukauden aikana?	0	1

Jos vastasit edellisen sivun kysymykseen **Ei**, siirry kohtaan 7. Jos vastasit **Kyllä**, vastaa alla oleviin kysymyksiin.

<i>Ympyröi sopiva vaihtoehto.</i>	Ei	Kyllä
Onko silmien kutinaa, vetistystä tai punoitusta esiintynyt vuodenaikoihin liittyen? Kyllä-vastauksessa ympyröi oikeat vaihtoehdot: tammi-, helmi-, maaliskuu-, huhti-, touko-, kesä-, heinä-, elokuu-, syys-, loka-, marraskuu-, joulukuussa	0	1
Onko silmien kutinaa, vetistystä tai punoitusta esiintynyt eläinkontakteihin liittyen?	0	1
Onko silmien kutinaa, vetistystä tai punoitusta esiintynyt jossain muussa tilanteessa? Kyllä-vastauksessa tilanteen kuvaus:	0	1

7. IHO-OIREET

<i>Ympyröikää sopiva vaihtoehto.</i>	Ei	Kyllä
Onko Sinulla ollut kutisevaa ihottumaa viimeisen 12 kuukauden aikana?	0	1

Jos vastasit **Ei**, siirry kohtaan 8. Jos vastasit **Kyllä**, vastaa alla olevaan kysymykseen.

<i>Ympyröi sopiva vaihtoehto.</i>	Ei	Kyllä
Onko kutisevaa ihottumaa esiintynyt nilkkojen etupuolella tai pakaroiden alapuolella, kaulan, korvien tai silmien alueella tai kyynär- tai polvitaiveissa?	0	1

8. SUKULAISTEN ASTMA

<i>Ympyröi sopiva vaihtoehto.</i>	Ei	Kyllä
Onko lääkäri koskaan todennut äidilläsi astmaa?	0	1
Onko lääkäri koskaan todennut isälläsi astmaa?	0	1
Onko lääkäri koskaan todennut sisaruksillasi astmaa?	0	1
Onko lääkäri koskaan todennut lapsillasi astmaa?	0	1

9. TUPAKOINTI

<i>Ympyröi sopiva vaihtoehto.</i>	Ei	Kyllä
Tupakoitko tällä hetkellä?	0	1
Kyllä-vastauksessa savukkeiden lukumäärä/vrk:		

10. PAINOINDEKSI

Paino	
Pituus	

MARJA RUOTSALAINEN

*Do Wheezing Infants Grow
Up to be Asthmatic Adults?*

*Asthma Prevalence in Relation to Early-Life
and Current Risk Factors*

Bronchiolitis is the most frequent infectious disease in infancy. It is known that if bronchiolitis require hospitalization, it is a major risk factor for subsequent wheezing and asthma. This study investigated the prevalence of asthma and allergy and the role of overweight on the prevalence of asthma after hospitalization for bronchiolitis in infancy. The increased asthma risk in children with early-life wheezing symptoms continues until at least 27 years of age.



UNIVERSITY OF
EASTERN FINLAND

PUBLICATIONS OF THE UNIVERSITY OF EASTERN FINLAND
Dissertations in Health Sciences

ISBN 978-952-61-1344-9